#
# List of summaries for testing.  Each line is the following format:
#
# Gene\tVariant\tTumorType\tGene Summary\tVariant Summary\tTumor Type Summary
#
ABL1	BCR-ABL1 Fusion	Acute Lymphoid Leukemia	ABL1, a tyrosine kinase, is frequently altered by chromosomal translocations in leukemia.	The BCR-ABL1 fusion is known to be oncogenic.	Imatinib and dasatinib is FDA-approved for the treatment of patients with BCR-ABL1 fusion positive acute lymphoid or chronic myelogenous leukemias.
ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	ABL1, a tyrosine kinase, is frequently altered by chromosomal translocations in leukemia.	The BCR-ABL1 fusion is known to be oncogenic.	Imatinib is FDA-approved for the treatment of patients with BCR-ABL1 fusion positive acute lymphoid or chronic myelogenous leukemia.
ABL1	BCR-ABL1 Fusion	Gastrointestinal Stromal Tumor	ABL1, a tyrosine kinase, is frequently altered by chromosomal translocations in leukemia.	The BCR-ABL1 fusion is known to be oncogenic.	While imatinib is FDA-approved for the treatment of patients with BCR-ABL1 fusion positive acute lymphoid or chronic myelogenous leukemia, its clinical utility in patients with BCR-ABL1 fusion positive gastrointestinal stromal tumors is unknown.
ABL1	NUP214-ABL1 fusion	Prostate Cancer	ABL1, a tyrosine kinase, is frequently altered by chromosomal translocations in leukemia.	The NUP214-ABL1 fusion is likely oncogenic.	While imatinib is FDA-approved for the treatment of patients with BCR-ABL1 fusion positive acute lymphoid or chronic myelogenous leukemia, its clinical utility in patients with ABL1-fusion positive prostate cancer is unknown.
AKT1	Q79K	Prostate Cancer	AKT1, an intracellular kinase, is mutated at low frequencies in a diverse range of cancers.	The AKT1 Q79K mutation is likely oncogenic.	While promising clinical data supports the use of pan-AKT targeted inhibitors such as AZD5363 in patients with AKT1 E17K mutant ER+ breast and gynecologic cancers, their clinical utility in patients with AKT1 Q79K mutant prostate cancer is unknown.
AKT1	AKT1-BCL11B fusion	Non-Small Cell Lung Cancer	AKT1, an intracellular kinase, is mutated at low frequencies in a diverse range of cancers.	As of 08/04/2017, there was no available functional data about the AKT1-BCL11B fusion.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AKT1-BCL11B fusion positive non-small cell lung cancer.
AKT1	G395S	Gastrointestinal Stromal Tumor	AKT1, an intracellular kinase, is mutated at low frequencies in a diverse range of cancers.	As of 08/04/2017, there was no available functional data about the AKT1 G395S mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AKT1 G395S mutant gastrointestinal stromal tumors.
AKT1	L213Gfs*24	Non-Small Cell Lung Cancer	AKT1, an intracellular kinase, is mutated at low frequencies in a diverse range of cancers.	As of 09/13/2017, there was no available functional data about the AKT1 L213Gfs*24 mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AKT1 L213Gfs*24 mutant non-small cell lung cancer.
AKT1	E17K	Breast Cancer	AKT1, an intracellular kinase, is mutated at low frequencies in a diverse range of cancers.	The AKT1 E17K mutation is known to be oncogenic.	There is promising clinical data in patients with AKT1 E17K mutant ER+ ductal breast cancer treated with the pan-AKT targeted inhibitor AZD5363.
AKT1	E17K	Ovarian Cancer	AKT1, an intracellular kinase, is mutated at low frequencies in a diverse range of cancers.	The AKT1 E17K mutation is known to be oncogenic.	There is promising clinical data in patients with AKT1 E17K mutant gynecological cancer treated with the pan-AKT targeted inhibitor AZD5363.
AKT1	E17K	Sex Cord Stromal Tumor	AKT1, an intracellular kinase, is mutated at low frequencies in a diverse range of cancers.	The AKT1 E17K mutation is known to be oncogenic.	While promising clinical data support the use of pan-AKT targeted inhibitors such as AZD5363 in patients with AKT1 E17K mutant ER+ breast and gynecologic cancers, their clinical utility in patients with AKT1 E17K mutant sex cord stromal tumors is unknown.
AKT1	E17R	Breast Cancer	AKT1, an intracellular kinase, is mutated at low frequencies in a diverse range of cancers.	The AKT1 E17R mutation has not been functionally or clinically validated. However, AKT1 E17K is known to be oncogenic, and therefore AKT1 E17R is considered likely oncogenic.	There is promising clinical data in patients with AKT1 E17K mutant ER+ ductal breast cancer treated with the pan-AKT targeted inhibitor AZD5363.
AKT1	E17R	Ovarian Cancer	AKT1, an intracellular kinase, is mutated at low frequencies in a diverse range of cancers.	The AKT1 E17R mutation has not been functionally or clinically validated. However, AKT1 E17K is known to be oncogenic, and therefore AKT1 E17R is considered likely oncogenic.	There is promising clinical data in patients with AKT1 E17K mutant gynecological cancer treated with the pan-AKT targeted inhibitor AZD5363.
AKT1	E17*	Germ Cell Tumor	AKT1, an intracellular kinase, is mutated at low frequencies in a diverse range of cancers.	As of 09/12/2017, there was no available functional data about the AKT1 E17* mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AKT1 E17* mutant germ cell tumors.
ALK	G616Dfs*49	Glioma	ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancers including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumor.	The ALK G616Dfs*49 mutation has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ALK G616Dfs*49 mutant glioma.
ALK	E1435del	Nerve Sheath Tumor	ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancers including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumor.	The ALK E1435del alteration has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with ALK E1435del altered nerve sheath tumors.
ALK	F1174L	Non-Small Cell Lung Cancer	ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancers including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumor.	The ALK F1174L mutation is known to be oncogenic.	In lung patients with a known ALK fusion and who have been treated with ALK targeted therapy, the ALK F1174L mutation has been reported as a secondary mutation that confers resistance to ALK inhibitors.
ALK	EML4-ALK fusion	Non-Small Cell Lung Cancer	ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancers including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumor.	The EML4-ALK fusion is known to be oncogenic.	Crizotinib, ceritinib, alectinib and brigatinib are FDA-approved for the treatment of patients with ALK-fusion positive lung cancer.
ALK	EML4-ALK fusion	Gastrointestinal Stromal Tumor	ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancers including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumor.	The EML4-ALK fusion is known to be oncogenic.	While crizotinib, ceritinib, alectinib and brigatinib are FDA-approved for the treatment of patients with ALK-fusion positive lung cancer, their clinical utility in patients with ALK-fusion positive gastrointestinal stromal tumors is unknown.
ALK	EML4-ALK fusion	Soft Tissue Sarcoma	ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancers including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumor.	The EML4-ALK fusion is known to be oncogenic.	Crizotinib and ceritinib are NCCN-compendium listed for the treatment of patients with ALK-fusion positive inflammatory myofibroblastic tumors.
ALK	L1196M	Non-Small Cell Lung Cancer	ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancers including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumor.	The ALK L1196M mutation is known to be oncogenic.	While crizotinib, ceritinib, alectinib and brigatinib are FDA-approved for the treatment of patients with ALK-fusion positive lung cancer, their clinical utility in patients with ALK L1196M mutant non-small cell lung cancer is unknown.
ALK	L1196Q	Non-Small Cell Lung Cancer	ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancers including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumor.	The ALK L1196Q mutation is known to be oncogenic.	While crizotinib, ceritinib, alectinib and brigatinib are FDA-approved for the treatment of patients with ALK-fusion positive lung cancer, their clinical utility in patients with ALK L1196Q mutant non-small cell lung cancer is unknown.
ALK	L1196M	Gastrointestinal Stromal Tumor	ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancers including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumor.	The ALK L1196M mutation is known to be oncogenic.	While crizotinib, ceritinib, alectinib and brigatinib are FDA-approved for the treatment of patients with ALK-fusion positive lung cancer, their clinical utility in patients with ALK L1196M mutant gastrointestinal stromal tumors is unknown.
ALK	L1196Q	Gastrointestinal Stromal Tumor	ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancers including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumor.	The ALK L1196Q mutation is known to be oncogenic.	While crizotinib, ceritinib, alectinib and brigatinib are FDA-approved for the treatment of patients with ALK-fusion positive lung cancer, their clinical utility in patients with ALK L1196Q mutant gastrointestinal stromal tumors is unknown.
ALK	L1196R	Non-Small Cell Lung Cancer	ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancers including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumor.	The ALK L1196R mutation has not been functionally or clinically validated. However, ALK L1196M/Q are known to be oncogenic, and therefore ALK L1196R is considered likely oncogenic.	While crizotinib, ceritinib, alectinib and brigatinib are FDA-approved for the treatment of patients with ALK-fusion positive lung cancer, their clinical utility in patients with ALK L1196R mutant non-small cell lung cancer is unknown.
ALK	L1196R	Gastrointestinal Stromal Tumor	ALK, a receptor tyrosine kinase, is recurrently altered by chromosomal rearrangements in various cancers including anaplastic large cell lymphoma, non-small cell lung cancer and inflammatory myofibroblastic tumor.	The ALK L1196R mutation has not been functionally or clinically validated. However, ALK L1196M/Q are known to be oncogenic, and therefore ALK L1196R is considered likely oncogenic.	While crizotinib, ceritinib, alectinib and brigatinib are FDA-approved for the treatment of patients with ALK-fusion positive lung cancer, their clinical utility in patients with ALK L1196R mutant gastrointestinal stromal tumors is unknown.
ARAF	F351L	Bladder Cancer	ARAF, an intracellular kinase, is infrequently altered by mutation or amplification in various cancers.	The ARAF F351L mutation is known to be oncogenic.	While there is promising laboratory and anecdotal clinical data that supports the use of the FDA-approved RAF-targeted inhibitor sorafenib in patients with ARAF S214A mutant non-Langherhans cell histiocytic disease and patients with ARAF S214C mutant lung cancer, the clinical utility of this inhibitor in patients with ARAF F351L mutant bladder cancer is unknown.
ARAF	S214A	Histiocytosis	ARAF, an intracellular kinase, is infrequently altered by mutation or amplification in various cancers.	The ARAF S214A mutation is likely oncogenic.	There is promising clinical data in patients with ARAF-mutant histiocytic disease treated with the FDA-approved RAF-inhibitor sorafenib.
ARAF	S214A	Gastrointestinal Stromal Tumor	ARAF, an intracellular kinase, is infrequently altered by mutation or amplification in various cancers.	The ARAF S214A mutation is likely oncogenic.	While there is promising laboratory and anecdotal clinical data that supports the use of the FDA-approved RAF-targeted inhibitor sorafenib in patients with ARAF S214A mutant non-Langherhans cell histiocytic disease and patients with ARAF S214C mutant lung cancer, the clinical utility of this inhibitor in patients with ARAF S214A mutant gastrointestinal stromal tumors is unknown.
ARAF	S214F	Gastrointestinal Stromal Tumor	ARAF, an intracellular kinase, is infrequently altered by mutation or amplification in various cancers.	The ARAF S214F mutation is known to be oncogenic.	While there is promising laboratory and anecdotal clinical data that supports the use of the FDA-approved RAF-targeted inhibitor sorafenib in patients with ARAF S214A mutant non-Langherhans cell histiocytic disease and patients with ARAF S214C mutant lung cancer, the clinical utility of this inhibitor in patients with ARAF S214F mutant gastrointestinal stromal tumors is unknown.
ARAF	S214F	Non-Small Cell Lung Cancer	ARAF, an intracellular kinase, is infrequently altered by mutation or amplification in various cancers.	The ARAF S214F mutation is known to be oncogenic.	There is promising laboratory and anecdotal clinical data that supports the use of the RAF-targeted FDA-approved inhibitor sorafenib in ARAF-mutant non-small cell lung cancer.
ARAF	S214P	Histiocytosis	ARAF, an intracellular kinase, is infrequently altered by mutation or amplification in various cancers.	The ARAF S214P mutation has not been functionally or clinically validated. However, ARAF S214C/F are known to be oncogenic, and therefore ARAF S214P is considered likely oncogenic.	There is promising clinical data in patients with ARAF-mutant histiocytic disease treated with the FDA-approved RAF-inhibitor sorafenib.
ARAF	S214Y	Non-Small Cell Lung Cancer	ARAF, an intracellular kinase, is infrequently altered by mutation or amplification in various cancers.	The ARAF S214Y mutation has not been functionally or clinically validated. However, ARAF S214C/F are known to be oncogenic, and therefore ARAF S214Y is considered likely oncogenic.	There is promising laboratory and anecdotal clinical data that supports the use of the RAF-targeted FDA-approved inhibitor sorafenib in ARAF-mutant non-small cell lung cancer.
ARAF	S214Y	Colorectal Cancer	ARAF, an intracellular kinase, is infrequently altered by mutation or amplification in various cancers.	The ARAF S214Y mutation has not been functionally or clinically validated. However, ARAF S214C/F are known to be oncogenic, and therefore ARAF S214Y is considered likely oncogenic.	While there is promising laboratory and anecdotal clinical data that supports the use of the FDA-approved RAF-targeted inhibitor sorafenib in patients with ARAF S214A mutant non-Langherhans cell histiocytic disease and patients with ARAF S214C mutant lung cancer, the clinical utility of this inhibitor in patients with ARAF S214Y mutant colorectal cancer is unknown.
BRAF	N486_P490del	Histiocytosis	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF N486_P490del alteration is likely oncogenic.	While the RAF-inhibitor vemurafenib is considered standard care for the treatment of patients with BRAF V600-mutant histiocytic neoplasia, its clinical utility in patients with BRAF N486_P490del altered histiocytosis is unknown.
BRAF	T599delinsIP	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF T599delinsIP alteration is known to be oncogenic.	While the RAF-inhibitors dabrafenib and vemurafenib, alone and in combination with the MEK-inhibitors trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E and V600K mutant melanoma, their clinical utility in patients with BRAF T599delinsIP altered melanoma is unknown.
BRAF	L505H	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L505H mutation is known to be oncogenic.	While the RAF-inhibitors dabrafenib and vemurafenib, alone and in combination with the MEK-inhibitors trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E and V600K mutant melanoma, their clinical utility in patients with BRAF L505H mutant melanoma is unknown.
BRAF	BRAF-MKRN1 fusion	Non-Small Cell Lung Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF-MKRN1 fusion is likely oncogenic.	While there is promising clinical data demonstrating the clinical utility of MEK1/2-targeted inhibitors such as trametinib in patients with BRAF fusion-positive melanoma and ovarian cancer, their clinical utility in patients with BRAF-MKRN1 fusion positive non-small cell lung cancer is unknown.
BRAF	N581I	Non-Small Cell Lung Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF N581I mutation is likely oncogenic.	While the RAF-inhibitors vemurafenib and dabrafenib, and dabrafenib in combination with the MEK-inhibitor trametinib are NCCN-compendium listed for the treatment of patients with BRAF V600E mutant non-small cell lung cancer, their clinical utility in patients with BRAF N581I mutant non-small cell lung cancer is unknown.
BRAF	G469R	Cancer of Unknown Primary	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF G469R mutation is likely oncogenic.	While the RAF-inhibitors dabrafenib and vemurafenib, alone and in combination with the MEK-inhibitors trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E and V600K mutant melanoma, their clinical utility in patients with BRAF G469R mutant cancer of unknown primary is unknown.
BRAF	L485W	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L485W mutation has not been functionally or clinically validated. However, BRAF L485F is likely oncogenic, and therefore BRAF L485W is considered likely oncogenic.	While the RAF-inhibitors dabrafenib and vemurafenib, alone and in combination with the MEK-inhibitors trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E and V600K mutant melanoma, their clinical utility in patients with BRAF L485W mutant melanoma is unknown.
BRAF	L485W	Bladder Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L485W mutation has not been functionally or clinically validated. However, BRAF L485F is likely oncogenic, and therefore BRAF L485W is considered likely oncogenic.	While the RAF-inhibitors dabrafenib and vemurafenib, alone and in combination with the MEK-inhibitors trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E and V600K mutant melanoma, their clinical utility in patients with BRAF L485W mutant bladder cancer is unknown.
BRAF	K601E	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF K601E mutation is likely oncogenic.	There is promising clinical data in patients with BRAF K601E mutant melanoma treated with the FDA-approved MEK-inhibitor trametinib. Therefore, patients with melanoma harboring the BRAF K601E mutation may be rational candidates for clinical trials investigating MEK-inhibitors.
BRAF	K601E	Salivary Gland Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF K601E mutation is likely oncogenic.	While there is promising clinical data supporting the use of the MEK-inhibitor trametinib in patients with BRAF K601E mutant melanoma, its clinical utility in patients with BRAF K601E mutant salivary gland cancer is unknown.
BRAF	K601N	Prostate Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF K601N mutation is likely oncogenic.	While there is promising clinical data supporting the use of the MEK-inhibitor trametinib in patients with BRAF K601E mutant melanoma, its clinical utility in patients with BRAF K601N mutant prostate cancer is unknown.
BRAF	K601N	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF K601N mutation is likely oncogenic.	There is promising clinical data in patients with BRAF K601E mutant melanoma treated with the FDA-approved MEK-inhibitor trametinib. Therefore, patients with melanoma harboring the BRAF K601N mutation may be rational candidates for clinical trials investigating MEK-inhibitors.
BRAF	L597Q	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L597Q mutation is likely oncogenic.	There is promising clinical data in patients with BRAF L597-mutant melanoma treated with the FDA-approved MEK-inhibitor trametinib. Therefore, patients with melanoma harboring the BRAF L597Q mutation may be rational candidates for clinical trials investigating MEK-inhibitors.
BRAF	L597R	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L597R mutation is likely oncogenic.	There is promising clinical data in patients with BRAF L597-mutant melanoma treated with the FDA-approved MEK-inhibitor trametinib. Therefore, patients with melanoma harboring the BRAF L597R mutation may be rational candidates for clinical trials investigating MEK-inhibitors.
BRAF	L597S	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L597S mutation is likely oncogenic.	There is promising clinical data in patients with BRAF L597-mutant melanoma treated with the FDA-approved MEK-inhibitor trametinib. Therefore, patients with melanoma harboring the BRAF L597S mutation may be rational candidates for clinical trials investigating MEK-inhibitors.
BRAF	L597V	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L597V mutation is known to be oncogenic.	There is promising clinical data in patients with BRAF L597-mutant melanoma treated with the FDA-approved MEK-inhibitor trametinib. Therefore, patients with melanoma harboring the BRAF L597V mutation may be rational candidates for clinical trials investigating MEK-inhibitors.
BRAF	L597Q	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L597Q mutation is likely oncogenic.	While there is promising clinical data supporting the use of the FDA-approved MEK-inhibitor trametinib in patients with BRAF L597-mutant melanoma, its clinical utility in patients with BRAF L597Q mutant colorectal cancer is unknown.
BRAF	L597R	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L597R mutation is likely oncogenic.	While there is promising clinical data supporting the use of the FDA-approved MEK-inhibitor trametinib in patients with BRAF L597-mutant melanoma, its clinical utility in patients with BRAF L597R mutant colorectal cancer is unknown.
BRAF	L597S	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L597S mutation is likely oncogenic.	While there is promising clinical data supporting the use of the FDA-approved MEK-inhibitor trametinib in patients with BRAF L597-mutant melanoma, its clinical utility in patients with BRAF L597S mutant colorectal cancer is unknown.
BRAF	L597V	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L597V mutation is known to be oncogenic.	While there is promising clinical data supporting the use of the FDA-approved MEK-inhibitor trametinib in patients with BRAF L597-mutant melanoma, its clinical utility in patients with BRAF L597V mutant colorectal cancer is unknown.
BRAF	L597P	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L597P mutation has not been functionally or clinically validated. However, BRAF L597V is known to be oncogenic, and therefore BRAF L597P is considered likely oncogenic.	There is promising clinical data in patients with BRAF L597-mutant melanoma treated with the FDA-approved MEK-inhibitor trametinib. Therefore, patients with melanoma harboring the BRAF L597P mutation may be rational candidates for clinical trials investigating MEK-inhibitors.
BRAF	L597P	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L597P mutation has not been functionally or clinically validated. However, BRAF L597V is known to be oncogenic, and therefore BRAF L597P is considered likely oncogenic.	While there is promising clinical data supporting the use of the FDA-approved MEK-inhibitor trametinib in patients with BRAF L597-mutant melanoma, its clinical utility in patients with BRAF L597P mutant colorectal cancer is unknown.
BRAF	L597P	Gastrointestinal Stromal Tumor	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF L597P mutation has not been functionally or clinically validated. However, BRAF L597V is known to be oncogenic, and therefore BRAF L597P is considered likely oncogenic.	While there is promising clinical data supporting the use of the FDA-approved MEK-inhibitor trametinib in patients with BRAF L597-mutant melanoma, its clinical utility in patients with BRAF L597P mutant gastrointestinal stromal tumors is unknown.
BRAF	MKRN1-BRAF Fusion	Breast Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The MKRN1-BRAF fusion is likely oncogenic.	While there is promising clinical data demonstrating the clinical utility of MEK1/2-targeted inhibitors such as trametinib in patients with BRAF fusion-positive melanoma and ovarian cancer, their clinical utility in patients with MKRN1-BRAF fusion positive breast cancer is unknown.
BRAF	CUL1-BRAF Fusion	Breast Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The CUL1-BRAF fusion is likely oncogenic.	While there is promising clinical data demonstrating the clinical utility of MEK1/2-targeted inhibitors such as trametinib in patients with BRAF fusion-positive melanoma and ovarian cancer, their clinical utility in patients with CUL1-BRAF fusion positive breast cancer is unknown.
BRAF	MKRN1-BRAF Fusion	Ovarian Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The MKRN1-BRAF fusion is likely oncogenic.	There is promising clinical data in patients with CUL1-BRAF fusion-positive ovarian cancer treated with the FDA-approved MEK-inhibitor selumetinib in combination with paclitaxel. Therefore, patients with MKRN1-BRAF fusion positive ovarian cancer may be rational candidates for clinical trials investigating MEK-inhibitors.
BRAF	CUL1-BRAF Fusion	Ovarian Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The CUL1-BRAF fusion is likely oncogenic.	There is promising clinical data in patients with CUL1-BRAF fusion-positive ovarian cancer treated with the FDA-approved MEK-inhibitor selumetinib in combination with paclitaxel. Therefore, patients with CUL1-BRAF fusion positive ovarian cancer may be rational candidates for clinical trials investigating MEK-inhibitors.
BRAF	V600E	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600E mutation is known to be oncogenic.	The FDA-approved selective RAF-inhibitors dabrafenib and vemurafenib have minimal activity as single agents in BRAF V600-mutant colorectal cancer. There is promising clinical data supporting regimens that combine a RAF-inhibitor together with an anti-EGFR antibody with or without a MEK-inhibitor, such as the doublet vemurafenib plus panitumumab or the triplet dabrafenib, trametinib, plus panitumumab in patients with these tumors.
BRAF	V600K	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600K mutation is known to be oncogenic.	The FDA-approved selective RAF-inhibitors dabrafenib and vemurafenib have minimal activity as single agents in BRAF V600-mutant colorectal cancer. There is promising clinical data supporting regimens that combine a RAF-inhibitor together with an anti-EGFR antibody with or without a MEK-inhibitor, such as the doublet vemurafenib plus panitumumab or the triplet dabrafenib, trametinib, plus panitumumab in patients with these tumors.
BRAF	V600M	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600M mutation is known to be oncogenic.	The FDA-approved selective RAF-inhibitors dabrafenib and vemurafenib have minimal activity as single agents in BRAF V600-mutant colorectal cancer. There is promising clinical data supporting regimens that combine a RAF-inhibitor together with an anti-EGFR antibody with or without a MEK-inhibitor, such as the doublet vemurafenib plus panitumumab or the triplet dabrafenib, trametinib, plus panitumumab in patients with these tumors.
BRAF	V600R	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600R mutation is known to be oncogenic.	The FDA-approved selective RAF-inhibitors dabrafenib and vemurafenib have minimal activity as single agents in BRAF V600-mutant colorectal cancer. There is promising clinical data supporting regimens that combine a RAF-inhibitor together with an anti-EGFR antibody with or without a MEK-inhibitor, such as the doublet vemurafenib plus panitumumab or the triplet dabrafenib, trametinib, plus panitumumab in patients with these tumors.
BRAF	V600D	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600D mutation is known to be oncogenic.	The FDA-approved selective RAF-inhibitors dabrafenib and vemurafenib have minimal activity as single agents in BRAF V600-mutant colorectal cancer. There is promising clinical data supporting regimens that combine a RAF-inhibitor together with an anti-EGFR antibody with or without a MEK-inhibitor, such as the doublet vemurafenib plus panitumumab or the triplet dabrafenib, trametinib, plus panitumumab in patients with these tumors.
BRAF	V600G	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600G mutation is likely oncogenic.	The FDA-approved selective RAF-inhibitors dabrafenib and vemurafenib have minimal activity as single agents in BRAF V600-mutant colorectal cancer. There is promising clinical data supporting regimens that combine a RAF-inhibitor together with an anti-EGFR antibody with or without a MEK-inhibitor, such as the doublet vemurafenib plus panitumumab or the triplet dabrafenib, trametinib, plus panitumumab in patients with these tumors.
BRAF	V600E	Histiocytosis	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600E mutation is known to be oncogenic.	The RAF-inhibitor vemurafenib is considered standard care for the treatment of patients with BRAF V600-mutant histiocytic neoplasia.
BRAF	V600K	Histiocytosis	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600K mutation is known to be oncogenic.	The RAF-inhibitor vemurafenib is considered standard care for the treatment of patients with BRAF V600-mutant histiocytic neoplasia.
BRAF	V600M	Histiocytosis	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600M mutation is known to be oncogenic.	The RAF-inhibitor vemurafenib is considered standard care for the treatment of patients with BRAF V600-mutant histiocytic neoplasia.
BRAF	V600R	Histiocytosis	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600R mutation is known to be oncogenic.	The RAF-inhibitor vemurafenib is considered standard care for the treatment of patients with BRAF V600-mutant histiocytic neoplasia.
BRAF	V600D	Histiocytosis	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600D mutation is known to be oncogenic.	The RAF-inhibitor vemurafenib is considered standard care for the treatment of patients with BRAF V600-mutant histiocytic neoplasia.
BRAF	V600G	Histiocytosis	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600G mutation is likely oncogenic.	The RAF-inhibitor vemurafenib is considered standard care for the treatment of patients with BRAF V600-mutant histiocytic neoplasia.
BRAF	V600E	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600E mutation is known to be oncogenic.	The RAF-inhibitors dabrafenib and vemurafenib, alone and in combination with the MEK-inhibitors trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E mutant melanoma. Data support using the combination therapies dabrafenib plus trametinib or vemurafenib plus cobimetinib in place of single agents dabrafenib, vemurafenib, or trametinib.
BRAF	V600K	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600K mutation is known to be oncogenic.	The MEK-inhibitor trametinib, alone or in combination with the RAF-inhibitor dabrafenib, and the combination of the MEK-inhibitor cobimetinib with the RAF-inhibitor vemurafenib are FDA-approved for the treatment of patients with BRAF V600K mutant melanoma. Data support using the combination therapies dabrafenib plus trametinib or vemurafenib plus cobimetinib in place of single agents dabrafenib, vemurafenib, or trametinib.
BRAF	V600M	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600M mutation is known to be oncogenic.	While the FDA-approval of the RAF-inhibitors dabrafenib and vemurafenib, alone and in combination with the MEK-inhibitors trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E mutant melanoma, these treatments are also considered standard care for treatment of patients with BRAF V600M mutant melanoma. Data support using the combination therapies dabrafenib plus trametinib or vemurafenib plus cobimetinib in place of single agents dabrafenib, vemurafenib, or trametinib.
BRAF	V600R	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600R mutation is known to be oncogenic.	While the FDA-approval of the RAF-inhibitors dabrafenib and vemurafenib, alone and in combination with the MEK-inhibitors trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E mutant melanoma, these treatments are also considered standard care for treatment of patients with BRAF V600R mutant melanoma. Data support using the combination therapies dabrafenib plus trametinib or vemurafenib plus cobimetinib in place of single agents dabrafenib, vemurafenib, or trametinib.
BRAF	V600D	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600D mutation is known to be oncogenic.	While the FDA-approval of the RAF-inhibitors dabrafenib and vemurafenib, alone and in combination with the MEK-inhibitors trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E mutant melanoma, these treatments are also considered standard care for treatment of patients with BRAF V600D mutant melanoma. Data support using the combination therapies dabrafenib plus trametinib or vemurafenib plus cobimetinib in place of single agents dabrafenib, vemurafenib, or trametinib.
BRAF	V600G	Melanoma	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600G mutation is likely oncogenic.	While the FDA-approval of the RAF-inhibitors dabrafenib and vemurafenib, alone and in combination with the MEK-inhibitors trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E mutant melanoma, these treatments are also considered standard care for treatment of patients with BRAF V600G mutant melanoma. Data support using the combination therapies dabrafenib plus trametinib or vemurafenib plus cobimetinib in place of single agents dabrafenib, vemurafenib, or trametinib.
BRAF	V600E	Non-Small Cell Lung Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600E mutation is known to be oncogenic.	The RAF-inhibitor dabrafenib in combination with the MEK-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant non-small cell lung cancer.
BRAF	V600K	Non-Small Cell Lung Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600K mutation is known to be oncogenic.	While the FDA-approval of combination dabrafenib and trametinib treatment specifies patients with BRAF V600E mutant non-small cell lung cancer (NSCLC), this combination is also considered standard care for treatment of patients with BRAF V600K mutant non-small cell lung cancer.
BRAF	V600M	Non-Small Cell Lung Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600M mutation is known to be oncogenic.	While the FDA-approval of combination dabrafenib and trametinib treatment specifies patients with BRAF V600E mutant non-small cell lung cancer (NSCLC), this combination is also considered standard care for treatment of patients with BRAF V600M mutant non-small cell lung cancer.
BRAF	V600R	Non-Small Cell Lung Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600R mutation is known to be oncogenic.	While the FDA-approval of combination dabrafenib and trametinib treatment specifies patients with BRAF V600E mutant non-small cell lung cancer (NSCLC), this combination is also considered standard care for treatment of patients with BRAF V600R mutant non-small cell lung cancer.
BRAF	V600D	Non-Small Cell Lung Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600D mutation is known to be oncogenic.	While the FDA-approval of combination dabrafenib and trametinib treatment specifies patients with BRAF V600E mutant non-small cell lung cancer (NSCLC), this combination is also considered standard care for treatment of patients with BRAF V600D mutant non-small cell lung cancer.
BRAF	V600G	Non-Small Cell Lung Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600G mutation is likely oncogenic.	While the FDA-approval of combination dabrafenib and trametinib treatment specifies patients with BRAF V600E mutant non-small cell lung cancer (NSCLC), this combination is also considered standard care for treatment of patients with BRAF V600G mutant non-small cell lung cancer.
BRAF	V600E	Gastrointestinal Stromal Tumor	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600E mutation is known to be oncogenic.	While the RAF-inhibitors dabrafenib and vemurafenib, alone and in combination with the MEK-inhibitors trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E mutant melanoma and non-small cell lung cancer, their clinical utility in patients with BRAF V600E mutant gastrointestinal stromal tumors is unknown.
BRAF	V600K	Gastrointestinal Stromal Tumor	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600K mutation is known to be oncogenic.	While the combination of the RAF-inhibitor dabrafenib with the MEK-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma and BRAF V600E mutant non-small cell lung cancer, the clinical utility of this combination in patients with BRAF V600K mutant gastrointestinal stromal tumors is unknown.
BRAF	V600M	Gastrointestinal Stromal Tumor	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600M mutation is known to be oncogenic.	While the combination of the RAF-inhibitor dabrafenib with the MEK-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma and BRAF V600E mutant non-small cell lung cancer, the clinical utility of this combination in patients with BRAF V600M mutant gastrointestinal stromal tumors is unknown.
BRAF	V600R	Gastrointestinal Stromal Tumor	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600R mutation is known to be oncogenic.	While the combination of the RAF-inhibitor dabrafenib with the MEK-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma and BRAF V600E mutant non-small cell lung cancer, the clinical utility of this combination in patients with BRAF V600R mutant gastrointestinal stromal tumors is unknown.
BRAF	V600D	Gastrointestinal Stromal Tumor	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600D mutation is known to be oncogenic.	While the combination of the RAF-inhibitor dabrafenib with the MEK-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma and BRAF V600E mutant non-small cell lung cancer, the clinical utility of this combination in patients with BRAF V600D mutant gastrointestinal stromal tumors is unknown.
BRAF	V600G	Gastrointestinal Stromal Tumor	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	The BRAF V600G mutation is likely oncogenic.	While the combination of the RAF-inhibitor dabrafenib with the MEK-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma and BRAF V600E mutant non-small cell lung cancer, the clinical utility of this combination in patients with BRAF V600G mutant gastrointestinal stromal tumors is unknown.
BRAF	R558Q	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	As of 08/01/2017, there was no available functional data about the BRAF R558Q mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRAF R558Q mutant colorectal cancer.
BRAF	P277Hfs*2	Colorectal Cancer	BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers.	As of 09/03/2017, there was no available functional data about the BRAF P277Hfs*2 mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with BRAF P277Hfs*2 mutant colorectal cancer.
BRCA1	W1782*	Gastrointestinal Stromal Tumor	BRCA1 is a tumor suppressor involved in the DNA damage response and can be mutated in various cancer types.	The BRCA1 W1782* mutation is likely oncogenic.	While PARP inhibitors rucaparib, olaparib and niraparib are FDA-approved for the treatment of patients with BRCA1-mutant ovarian cancer (olaparib only in the germline setting), their clinical utility in patients with gastrointestinal stromal tumors harboring the somatic BRCA1 W1782* mutation is unknown.
BRCA1	V1713A	Ovarian Cancer	BRCA1 is a tumor suppressor involved in the DNA damage response and can be mutated in various cancer types.	The BRCA1 V1713A mutation is known to be oncogenic.	PARP-inhibitors rucaparib, olaparib and niraparib are FDA-approved for the treatment of patients with BRCA1-mutant ovarian cancer who have received prior lines of therapy. Olaparib is only FDA-approved in the germline setting and is considered standard care for the treatment of BRCA1-mutant ovarian cancers in the somatic setting, niraparib is FDA-approved irrespective of BRCA mutation status and rucaparib is FDA-approved in both the germline and somatic setting for these patients.
BRCA2	S683Rfs*46	Breast Cancer	BRCA2 is a tumor suppressor involved in the DNA damage response and can be mutated in various cancer types.	The BRCA2 S683Rfs*46 mutation is likely oncogenic.	While PARP inhibitors rucaparib, olaparib and niraparib are FDA-approved for the treatment of patients with BRCA2-mutant ovarian cancer (olaparib only in the germline setting), their clinical utility in patients with breast cancer harboring the somatic BRCA2 S683Rfs*46 mutation is unknown.
BRCA2	R2336H	Ovarian Cancer	BRCA2 is a tumor suppressor involved in the DNA damage response and can be mutated in various cancer types.	The BRCA2 R2336H mutation is likely oncogenic.	PARP-inhibitors rucaparib, olaparib and niraparib are FDA-approved for the treatment of patients with BRCA2-mutant ovarian cancer who have received prior lines of therapy. Olaparib is only FDA-approved in the germline setting and is considered standard care for the treatment of BRCA2-mutant ovarian cancers in the somatic setting, niraparib is FDA-approved irrespective of BRCA mutation status and rucaparib is FDA-approved in both the germline and somatic setting for these patients.
CDK4	R24C	Melanoma	CDK4, an intracellular kinase, is altered by amplification or mutation in a diverse range of cancers including liposarcomas.	The CDK4 R24C mutation is known to be oncogenic.	While palbociclib is NCCN-compendium listed for the treatment of patients with well-differentiated and dedifferentiated liposarcomas, its clinical utility in patients with CDK4 R24C mutant melanoma is unknown.
CDK4	K22A	Bladder Cancer	CDK4, an intracellular kinase, is altered by amplification or mutation in a diverse range of cancers including liposarcomas.	The CDK4 K22A mutation is known to be oncogenic.	While palbociclib is NCCN-compendium listed for the treatment of patients with well-differentiated and dedifferentiated liposarcomas, its clinical utility in patients with CDK4 K22A mutant bladder cancer is unknown.
CDK4	K22M	Bladder Cancer	CDK4, an intracellular kinase, is altered by amplification or mutation in a diverse range of cancers including liposarcomas.	The CDK4 K22M mutation has not been functionally or clinically validated. However, CDK4 K22A is known to be oncogenic, and therefore CDK4 K22M is considered likely oncogenic.	While palbociclib is NCCN-compendium listed for the treatment of patients with well-differentiated and dedifferentiated liposarcomas, its clinical utility in patients with CDK4 K22M mutant bladder cancer is unknown.
CDK4	Amplification	Gastrointestinal Stromal Tumor	CDK4, an intracellular kinase, is altered by amplification or mutation in a diverse range of cancers including liposarcomas.	CDK4 amplification is known to be oncogenic.	While palbociclib is NCCN-compendium listed for the treatment of patients with well-differentiated and dedifferentiated liposarcomas, its clinical utility in patients with CDK4-amplified gastrointestinal stromal tumors is unknown.
CDK4	Amplification	Soft Tissue Sarcoma	CDK4, an intracellular kinase, is altered by amplification or mutation in a diverse range of cancers including liposarcomas.	CDK4 amplification is known to be oncogenic.	Well-differentiated and dedifferentiated liposarcomas are enriched for the presence of high-level CDK4 amplification and the CDK4/6 inhibitor, palbociclib, is NCCN-compendium listed for the treatment of patients with these tumor types. However, its clinical utility in other types of sarcoma is unknown.
EGFR	729_761del	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR 729_761del alteration is known to be oncogenic.	The EGFR tyrosine kinase inhibitors erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer harboring an EGFR exon 19 deletion such as 729_761del.
EGFR	729_761delins	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR 729_761delins alteration has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR 729_761delins altered non-small cell lung cancer.
EGFR	729_761ins	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR 729_761ins alteration is known to be oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC). Patients with NSCLC harboring EGFR exon 19 insertions such as 729_761ins have experienced clinical benefit following treatment with an EGFR TKI.
EGFR	762_823ins	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR 762_823ins alteration is known to be oncogenic.	Non-small lung cancer (NSCLC) harboring EGFR exon 20 insertions do not respond to the EGFR tyrosine kinase inhibitors erlotinib, afatinib and gefitinib. Patients with NSCLC harboring EGFR exon 20 insertions would be rational candidates for clinical trials investigating novel exon 20 targeted inhibitors.
EGFR	A289T	Glioma	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR A289T mutation has not been functionally or clinically validated. However, EGFR A289V is known to be oncogenic, and therefore EGFR A289T is considered likely oncogenic.	While EGFR tyrosine kinase inhibitors (TKIs) erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer, their clinical utility for patients with glioma harboring the EGFR A289T mutation is unknown.
EGFR	A289T	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR A289T mutation has not been functionally or clinically validated. However, EGFR A289V is known to be oncogenic, and therefore EGFR A289T is considered likely oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC).
EGFR	A289V	Glioma	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR A289V mutation is known to be oncogenic.	While EGFR tyrosine kinase inhibitors (TKIs) erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer, their clinical utility for patients with glioma harboring the EGFR A289V mutation is unknown.
EGFR	A289V	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR A289V mutation is known to be oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC).
EGFR	A763_Y764insFQEA	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR A763_Y764insFQEA alteration is known to be oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC). While patients with NSCLC harboring EGFR exon 20 insertions typically do not respond to EGFR TKIs, patients with the EGFR A763_Y764insFQEA exon 20 insertion have experience clinical benefit following treatment with an EGFR TKI.
EGFR	D761Y	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR D761Y mutation has not been functionally or clinically validated. However, EGFR D761N is likely oncogenic, and therefore EGFR D761Y is considered likely oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC).
EGFR	D761Y	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR D761Y mutation has not been functionally or clinically validated. However, EGFR D761N is likely oncogenic, and therefore EGFR D761Y is considered likely oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC).
EGFR	E709_T710delinsD	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR E709_T710delinsD alteration is known to be oncogenic.	The EGFR tyrosine kinase inhibitors (TKIs) erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC). Patients with NSCLC harboring the exon 18 EGFR E709_T710delinsD alteration can respond to EGFR TKIs.
EGFR	E709K	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR E709K mutation is known to be oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib or gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC). Patients with NSCLC harboring the exon 18 hotspot E709K mutation typically have a coincident EGFR-TKI sensitizing mutation such as L858R or G719 and can respond to EGFR TKIs.
EGFR	EGFR-KDD	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR-KDD mutation is known to be oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC). Patients with NSCLC harboring the EGFR-KDD alteration have experienced clinical benefit following treatment with an EGFR TKI.
EGFR	G598V	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR G598V mutation is known to be oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC).
EGFR	G719A	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR G719A mutation is known to be oncogenic.	The EGFR tyrosine kinase inhibitors erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC) and NCCN-compendium listed for the treatment of patients with EGFR G719A mutant NSCLC.
EGFR	G719C	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR G719C mutation is likely oncogenic.	The EGFR tyrosine kinase inhibitors erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC) and NCCN-compendium listed for the treatment of patients with EGFR G719C mutant NSCLC.
EGFR	G719D	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR G719D mutation has not been functionally or clinically validated. However, EGFR G719A/S are known to be oncogenic, and therefore EGFR G719D is considered likely oncogenic.	The EGFR tyrosine kinase inhibitors erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC) and NCCN-compendium listed for the treatment of patients with EGFR G719A mutant NSCLC.
EGFR	G719S	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR G719S mutation is known to be oncogenic.	The EGFR tyrosine kinase inhibitors erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC) and NCCN-compendium listed for the treatment of patients with EGFR G719S mutant NSCLC.
EGFR	H773dup	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR H773dup alteration is known to be oncogenic.	Non-small lung cancer (NSCLC) harboring EGFR exon 20 insertions do not respond to the EGFR tyrosine kinase inhibitors erlotinib, afatinib and gefitinib. Patients with NSCLC harboring EGFR exon 20 insertions would be rational candidates for clinical trials investigating novel exon 20 targeted inhibitors.
EGFR	H773R	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR H773R mutation has not been functionally or clinically validated. However, EGFR H773L is known to be oncogenic, and therefore EGFR H773R is considered likely oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC).
EGFR	L747P	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR L747P mutation is known to be oncogenic.	The EGFR tyrosine kinase inhibitors (TKIs) erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC). Patients with NSCLC harboring the exon 19 L747P mutation can respond to EGFR TKIs.
EGFR	L858R	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR L858R mutation is known to be oncogenic.	The EGFR tyrosine kinase inhibitors erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with EGFR L858R mutant non-small cell lung cancer.
EGFR	L861Q	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR L861Q mutation is known to be oncogenic.	The EGFR tyrosine kinase inhibitors erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC) and NCCN-compendium listed for the treatment of patients with EGFR L861Q mutant NSCLC.
EGFR	L861R	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR L861R mutation is known to be oncogenic.	The EGFR tyrosine kinase inhibitors erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC) and NCCN-compendium listed for the treatment of patients with EGFR L861R mutant NSCLC.
EGFR	R108K	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR R108K mutation is known to be oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC).
EGFR	R776C	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR R776C mutation is likely oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC).
EGFR	S720F	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	As of 08/18/2017, there was no available functional data about the EGFR S720F mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR S720F mutant non-small cell lung cancer.
EGFR	S768I	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR S768I mutation is known to be oncogenic.	The EGFR tyrosine kinase inhibitors erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC) and NCCN-compendium listed for the treatment of patients with EGFR S768I mutant NSCLC.
EGFR	T263P	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR T263P mutation is known to be oncogenic.	EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, afatinib and gefitinib are FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC).
EGFR	T790M	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR T790M mutation is known to be oncogenic.	While patients with EGFR T790M mutant non-small cell lung cancer do not respond to first or second-generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib, afatinib and gefitinib, the FDA-approved third-generation EGFR TKI, osimertinib, is associated with clinical benefit in these patients and is an appropriate treatment option.
EGFR	T854S	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	The EGFR T854S mutation has not been functionally or clinically validated.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR T854S mutant non-small cell lung cancer.
EGFR	L692F	Non-Small Cell Lung Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	As of 08/18/2017, there was no available functional data about the EGFR L692F mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR L692F mutant non-small cell lung cancer.
EGFR	L692F	Colorectal Cancer	EGFR, a receptor tyrosine kinase, is altered by amplification, mutation and/or overexpression in various cancers, most frequently in lung and brain cancers.	As of 08/18/2017, there was no available functional data about the EGFR L692F mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with EGFR L692F mutant colorectal cancer.
ERBB2	V777L	Breast Cancer	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	The ERBB2 V777L mutation is known to be oncogenic.	There is promising clinical data in patients with breast cancer harboring oncogenic ERBB2 mutations treated with the ERBB-targeted inhibitor neratinib.
ERBB2	V777M	Breast Cancer	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	The ERBB2 V777M mutation is likely neutral.	There is promising clinical data in patients with breast cancer harboring oncogenic ERBB2 mutations treated with the ERBB-targeted inhibitor neratinib.
ERBB2	G778_P780dup	Melanoma	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	The ERBB2 G778_P780dup alteration is known to be oncogenic.	While there is promising clinical data supporting the use of the ERBB-targeted inhibitor neratinib in patients with breast and non-small cell lung cancer harboring oncogenic ERBB2 alterations, its clinical utility in patients with ERBB2 G778_P780dup altered melanoma is unknown.
ERBB2	IKZF3-ERBB2 fusion	Breast Cancer	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	As of 07/10/2017, there was no available functional data about the IKZF3-ERBB2 fusion.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with IKZF3-ERBB2 fusion positive breast cancer.
ERBB2	Amplification	Breast Cancer	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	ERBB2 amplification is known to be oncogenic.	Trastuzumab and other anti-HER2 targeted therapies are FDA-approved for the treatment of patients with ERBB2-amplified, HER2-positive breast cancer.
ERBB2	Amplification	Esophagogastric Cancer	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	ERBB2 amplification is known to be oncogenic.	Trastuzumab in combination with chemotherapy is FDA-approved for the treatment of patients with ERBB2-amplified, HER2-positive gastric cancer.
ERBB2	Amplification	Melanoma	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	ERBB2 amplification is known to be oncogenic.	While the anti-HER2 targeted therapy trastuzumab is FDA-approved for the treatment of patients with ERBB2-amplified, HER2-positive breast and gastric cancers, its clinical utility in patients with ERBB2-amplified melanoma is unknown.
ERBB2	V659E	Breast Cancer	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	The ERBB2 V659E mutation is known to be oncogenic.	There is promising clinical data supporting the use of the anti-ERBB inhibitor neratinib in patients with breast cancer harboring activating ERBB2 alterations such as V659E. Therefore, patients with ERBB2 V659E mutant breast cancer may be rational candidates for clinical trials investigating ERBB-inhibitors.
ERBB2	V659E	Non-Small Cell Lung Cancer	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	The ERBB2 V659E mutation is known to be oncogenic.	There is promising clinical data in patients with non-small cell lung cancer harboring oncogenic ERBB2 mutations treated with the ERBB-targeted inhibitor neratinib.
ERBB2	V659E	Gastrointestinal Stromal Tumor	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	The ERBB2 V659E mutation is known to be oncogenic.	While there is promising clinical data supporting the use of the ERBB-targeted inhibitor neratinib in patients with breast and non-small cell lung cancer harboring oncogenic ERBB2 alterations, its clinical utility in patients with ERBB2 V659E mutant gastrointestinal stromal tumors is unknown.
ERBB2	V659N	Melanoma	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	The ERBB2 V659N mutation has not been functionally or clinically validated. However, ERBB2 V659E is known to be oncogenic, and therefore ERBB2 V659N is considered likely oncogenic.	While there is promising clinical data supporting the use of the ERBB-targeted inhibitor neratinib in patients with breast and non-small cell lung cancer harboring oncogenic ERBB2 alterations, its clinical utility in patients with ERBB2 V659N mutant melanoma is unknown.
ERBB2	V659N	Breast Cancer	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	The ERBB2 V659N mutation has not been functionally or clinically validated. However, ERBB2 V659E is known to be oncogenic, and therefore ERBB2 V659N is considered likely oncogenic.	There is promising clinical data supporting the use of the anti-ERBB inhibitor neratinib in patients with breast cancer harboring activating ERBB2 alterations such as V659N. Therefore, patients with ERBB2 V659N mutant breast cancer may be rational candidates for clinical trials investigating ERBB-inhibitors.
ERBB2	V659N	Non-Small Cell Lung Cancer	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	The ERBB2 V659N mutation has not been functionally or clinically validated. However, ERBB2 V659E is known to be oncogenic, and therefore ERBB2 V659N is considered likely oncogenic.	There is promising clinical data in patients with non-small cell lung cancer harboring oncogenic ERBB2 mutations treated with the ERBB-targeted inhibitor neratinib.
ERBB2	V659N	Gastrointestinal Stromal Tumor	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	The ERBB2 V659N mutation has not been functionally or clinically validated. However, ERBB2 V659E is known to be oncogenic, and therefore ERBB2 V659N is considered likely oncogenic.	While there is promising clinical data supporting the use of the ERBB-targeted inhibitor neratinib in patients with breast and non-small cell lung cancer harboring oncogenic ERBB2 alterations, its clinical utility in patients with ERBB2 V659N mutant gastrointestinal stromal tumors is unknown.
ERBB2	fusion	Breast cancer	ERBB2, a receptor tyrosine kinase, is altered by amplification and/or overexpression in various cancers, most frequently in breast, esophagogastric and endometrial cancers.	The fusion has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with fusion positive breast cancer.
FGFR1	N546K	Glioma	FGFR1, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in a diverse range of cancers, including lung and breast cancers.	The FGFR1 N546K mutation has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR1 N546K mutant glioma.
FGFR1	CLVS1-FGFR1 fusion	Colorectal Cancer	FGFR1, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in a diverse range of cancers, including lung and breast cancers.	The CLVS1-FGFR1 fusion is likely oncogenic.	While there is promising clinical data supporting the use of FGFR-targeted inhibitors such as dovitinib and AZD4547 in patients with FGFR1-amplified breast and lung cancer respectively, their clinical utility in patients with CLVS1-FGFR1 fusion positive colorectal cancer is unknown.
FGFR1	E664K	Skin Cancer	FGFR1, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in a diverse range of cancers, including lung and breast cancers.	The FGFR1 E664K mutation is likely neutral.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR1 E664K mutant skin cancer.
FGFR1	Amplification	Breast Cancer	FGFR1, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in a diverse range of cancers, including lung and breast cancers.	FGFR1 amplification is known to be oncogenic.	While there is promising clinical data supporting the use of pan-FGFR targeted inhibitors such as Debio1347, BGJ398, JNJ-42756493, and AZD4547 in patients with high-level FGFR1-amplified squamous cell lung cancer, their clinical utility in patients with FGFR1-amplified breast cancer is unknown.
FGFR1	Amplification	Non-Small Cell Lung Cancer	FGFR1, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in a diverse range of cancers, including lung and breast cancers.	FGFR1 amplification is known to be oncogenic.	There is promising clinical data supporting the use of pan-FGFR targeted inhibitors such as Debio1347, BGJ398, JNJ-42756493, and AZD4547 in patients with high-level FGFR1-amplified lung squamous cell carcinoma.
FGFR1	Amplification	Gastrointestinal Stromal Tumor	FGFR1, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in a diverse range of cancers, including lung and breast cancers.	FGFR1 amplification is known to be oncogenic.	While there is promising clinical data supporting the use of pan-FGFR targeted inhibitors such as Debio1347, BGJ398, JNJ-42756493, and AZD4547 in patients with high-level FGFR1-amplified squamous cell lung cancer, their clinical utility in patients with FGFR1-amplified gastrointestinal stromal tumors is unknown.
FGFR2	R664W	Adrenocortical Carcinoma	FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers including breast and esophagogastric cancers.	As of 08/05/2017, there was no available functional data about the FGFR2 R664W mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR2 R664W mutant adrenocortical carcinoma.
FGFR2	N549T	Adrenocortical Carcinoma	FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers including breast and esophagogastric cancers.	The FGFR2 N549T mutation is likely oncogenic.	While there is promising clinical data in specific tumor types supporting the use of FGFR-targeted inhibitors such as JNJ-42756493 and BGJ398 in patients with FGFR-fusion-positive cancers, their clinical utility in patients with FGFR2 N549T mutant adrenocortical carcinoma is unknown.
FGFR2	Amplification	Breast Cancer	FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers including breast and esophagogastric cancers.	FGFR2 amplification is known to be oncogenic.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR2-amplified breast cancer.
FGFR2	Amplification	Gastrointestinal Stromal Tumor	FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers including breast and esophagogastric cancers.	FGFR2 amplification is known to be oncogenic.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FGFR2-amplified gastrointestinal stromal tumors.
FGFR2	KIF14-FGFR2 fusion	Adrenocortical Carcinoma	FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers including breast and esophagogastric cancers.	The KIF14-FGFR2 fusion is likely oncogenic.	While there is promising clinical data supporting the use of pan-FGFR targeted inhibitors such as Debio-1347, BGJ398, JNJ-42756493 and AZD4575 in patients with FGFR2-fusion positive cholangiocarcinoma and urothelial cancers, their clinical utility in patients with KIF14-FGFR2 fusion positive adrenocortical carcinoma is unknown.
FGFR2	FGFR2-MARVELD3 fusion	Bladder Cancer	FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers including breast and esophagogastric cancers.	The FGFR2-MARVELD3 fusion is likely oncogenic.	There is promising clinical data in patients with FGFR2-fusion positive urothelial cancers treated with pan-FGFR-targeted inhibitors such as Debio1347, BGJ-398, JNJ-42756493 and AZD4575.
FGFR2	PALLD-FGFR2 fusion	Cholangiocarcinoma	FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers including breast and esophagogastric cancers.	The PALLD-FGFR2 fusion is likely oncogenic.	There is promising clinical data in patients with FGFR2-fusion positive cholangiocarcinomas treated with pan-FGFR-targeted inhibitors such as Debio1347, BGJ-398, JNJ-42756493 and AZD4575.
FGFR2	GFR2-MARVELD3 fusion	Endometrial Cancer	FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers including breast and esophagogastric cancers.	The GFR2-MARVELD3 fusion is likely oncogenic.	While there is promising clinical data supporting the use of pan-FGFR targeted inhibitors such as Debio-1347, BGJ398, JNJ-42756493 and AZD4575 in patients with FGFR2-fusion positive cholangiocarcinoma and urothelial cancers, their clinical utility in patients with GFR2-MARVELD3 fusion positive endometrial cancer is unknown.
FGFR2	KIF14-FGFR2 fusion	Cancer of Unknown Primary	FGFR2, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers including breast and esophagogastric cancers.	The KIF14-FGFR2 fusion is likely oncogenic.	While there is promising clinical data supporting the use of pan-FGFR targeted inhibitors such as Debio-1347, BGJ398, JNJ-42756493 and AZD4575 in patients with FGFR2-fusion positive cholangiocarcinoma and urothelial cancers, their clinical utility in patients with KIF14-FGFR2 fusion positive cancer of unknown primary is unknown.
FGFR3	K650E	Glioma	FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.	The FGFR3 K650E mutation is likely oncogenic.	While there is promising clinical data in patients with hotspot activating FGFR3 mutant urothelial cancers treated with pan FGFR-targeted inhibitors such as Debio1347, BGJ-398, JNJ-42756493 and AZD4575, their clinical utility in patients with glioma harboring the hotspot activating FGFR3 K650E mutation is unknown.
FGFR3	FGFR3-TACC3 Fusion	Adrenocortical Carcinoma	FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.	The FGFR3-TACC3 fusion is known to be oncogenic.	While there is promising clinical data supporting the use of pan-FGFR targeted inhibitors such as Debio1347, BGJ-398, JNJ-42756493 and AZD4575 in patients with FGFR3-fusion positive urothelial cancers, their clinical utility in patients with FGFR3-fusion positive adrenocortical carcinoma is unknown.
FGFR3	FGFR3-TACC3 Fusion	Bladder Cancer	FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.	The FGFR3-TACC3 fusion is known to be oncogenic.	There is promising clinical data in patients with FGFR3-fusion positive urothelial cancers treated with pan-FGFR-targeted inhibitors such as Debio1347, BGJ-398, JNJ-42756493 and AZD4575.
FGFR3	FGFR3-TACC3 Fusion	Glioma	FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.	The FGFR3-TACC3 fusion is known to be oncogenic.	While there is promising clinical data supporting the use of pan-FGFR targeted inhibitors such as Debio1347, BGJ-398, JNJ-42756493 and AZD4575 in patients with FGFR3-fusion positive urothelial cancers, their clinical utility in patients with FGFR3-fusion positive glioma is unknown.
FGFR3	FGFR3-TACC3 Fusion	Prostate Cancer	FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.	The FGFR3-TACC3 fusion is known to be oncogenic.	While there is promising clinical data supporting the use of pan-FGFR targeted inhibitors such as Debio1347, BGJ-398, JNJ-42756493 and AZD4575 in patients with FGFR3-fusion positive urothelial cancers, their clinical utility in patients with FGFR3-fusion positive prostate cancer is unknown.
FGFR3	WHSC1-FGFR3 fusion	Adrenocortical Carcinoma	FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.	The WHSC1-FGFR3 fusion is likely oncogenic.	While there is promising clinical data supporting the use of pan-FGFR targeted inhibitors such as Debio1347, BGJ-398, JNJ-42756493 and AZD4575 in patients with FGFR3-fusion positive urothelial cancers, their clinical utility in patients with FGFR3-fusion positive adrenocortical carcinoma is unknown.
FGFR3	TNIP2-FGFR3 fusion	Bladder Cancer	FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.	The TNIP2-FGFR3 fusion is likely oncogenic.	There is promising clinical data in patients with FGFR3-fusion positive urothelial cancers treated with pan-FGFR-targeted inhibitors such as Debio1347, BGJ-398, JNJ-42756493 and AZD4575.
FGFR3	ST7L-FGFR3 fusion	Glioma	FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.	The ST7L-FGFR3 fusion is likely oncogenic.	While there is promising clinical data supporting the use of pan-FGFR targeted inhibitors such as Debio1347, BGJ-398, JNJ-42756493 and AZD4575 in patients with FGFR3-fusion positive urothelial cancers, their clinical utility in patients with FGFR3-fusion positive glioma is unknown.
FGFR3	FGFR3-WHSC1 fusion	Breast Cancer	FGFR3, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplification in various cancers, most frequently in bladder cancer.	The FGFR3-WHSC1 fusion is likely oncogenic.	While there is promising clinical data supporting the use of pan-FGFR targeted inhibitors such as Debio1347, BGJ-398, JNJ-42756493 and AZD4575 in patients with FGFR3-fusion positive urothelial cancers, their clinical utility in patients with FGFR3-fusion positive breast cancer is unknown.
FLT3	N676S	Endometrial Cancer	FLT3, a receptor tyrosine kinase, is recurrently altered in acute myeloid leukemia and other hematologic malignancies.	The FLT3 N676S mutation is likely oncogenic.	While there is promising clinical data supporting the use of sorafenib in patients with FLT3 Y572_Y630ins altered acute myeloid leukemia, its clinical utility in patients with FLT3 N676S mutant endometrial cancer is unknown.
FLT3	D324N	Glioma	FLT3, a receptor tyrosine kinase, is recurrently altered in acute myeloid leukemia and other hematologic malignancies.	The FLT3 D324N mutation is likely neutral.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FLT3 D324N mutant glioma.
FLT3	Y572_Y630ins	Acute Myeloid Leukemia	FLT3, a receptor tyrosine kinase, is recurrently altered in acute myeloid leukemia and other hematologic malignancies.	The FLT3 Y572_Y630ins alteration is known to be oncogenic.	There is promising clinical data in patients with FLT3 Y572_Y630ins altered acute myeloid leukemia treated with the FDA-approved RAF-inhibitor sorafenib. Therefore patients with acute myeloid leukemia harboring the FLT3 Y572_Y630ins alteration may be rational candidates for clinical trials investigating novel RAF-inhibitors.
FLT3	Y572_Y630ins	Gastrointestinal Stromal Tumor	FLT3, a receptor tyrosine kinase, is recurrently altered in acute myeloid leukemia and other hematologic malignancies.	The FLT3 Y572_Y630ins alteration is known to be oncogenic.	While there is promising clinical data supporting the use of sorafenib in patients with FLT3 Y572_Y630ins altered acute myeloid leukemia, its clinical utility in patients with FLT3 Y572_Y630ins altered gastrointestinal stromal tumors is unknown.
IDH1	Y139D	Acute Myeloid Leukemia	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.	The IDH1 Y139D mutation is likely oncogenic.	While there is promising clinical data supporting the use of IDH1-targeted inhibitors such as AG120 in patients with IDH1 R132-mutant acute myeloid leukemia, their clinical utility in patients with IDH1 Y139D mutant acute myeloid leukemia is unknown.
IDH1	Y139D	Glioma	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.	The IDH1 Y139D mutation is likely oncogenic.	While there is promising clinical data supporting the use of IDH1-targeted inhibitors such as AG120 in patients with IDH1 R132-mutant acute myeloid leukemia, their clinical utility in patients with IDH1 Y139D mutant glioma is unknown.
IDH1	R132I	Acute Myeloid Leukemia	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.	The IDH1 R132I mutation has not been functionally or clinically validated. However, IDH1 R132C/G/H are known to be oncogenic, and therefore IDH1 R132I is considered likely oncogenic.	There is promising clinical data in patients with IDH1 R132-mutant acute myeloid leukemia treated with the IDH1-inhibitor AG-120. Therefore patients with acute myeloid leukemia harboring the IDH1 R132I mutation may be rational candidates for clinical trials investigating IDH1-inhibitors.
IDH1	R132C	Acute Myeloid Leukemia	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.	The IDH1 R132C mutation is known to be oncogenic.	There is promising clinical data in patients with IDH1 R132-mutant acute myeloid leukemia treated with the IDH1-inhibitor AG-120. Therefore patients with acute myeloid leukemia harboring the IDH1 R132C mutation may be rational candidates for clinical trials investigating IDH1-inhibitors.
IDH1	R132G	Acute Myeloid Leukemia	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.	The IDH1 R132G mutation is known to be oncogenic.	There is promising clinical data in patients with IDH1 R132-mutant acute myeloid leukemia treated with the IDH1-inhibitor AG-120. Therefore patients with acute myeloid leukemia harboring the IDH1 R132G mutation may be rational candidates for clinical trials investigating IDH1-inhibitors.
IDH1	R132H	Acute Myeloid Leukemia	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.	The IDH1 R132H mutation is known to be oncogenic.	There is promising clinical data in patients with IDH1 R132-mutant acute myeloid leukemia treated with the IDH1-inhibitor AG-120. Therefore patients with acute myeloid leukemia harboring the IDH1 R132H mutation may be rational candidates for clinical trials investigating IDH1-inhibitors.
IDH1	R132Q	Acute Myeloid Leukemia	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.	The IDH1 R132Q mutation is likely oncogenic.	There is promising clinical data in patients with IDH1 R132-mutant acute myeloid leukemia treated with the IDH1-inhibitor AG-120. Therefore patients with acute myeloid leukemia harboring the IDH1 R132Q mutation may be rational candidates for clinical trials investigating IDH1-inhibitors.
IDH1	R132C	Glioma	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.	The IDH1 R132C mutation is known to be oncogenic.	There is promising clinical data in patients with IDH1 R132-mutant glioma treated with the IDH1-inhibitor AG-120. Therefore patients with glioma harboring the IDH1 R132C mutation may be rational candidates for clinical trials investigating IDH1-inhibitors.
IDH1	R132G	Glioma	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.	The IDH1 R132G mutation is known to be oncogenic.	There is promising clinical data in patients with IDH1 R132-mutant glioma treated with the IDH1-inhibitor AG-120. Therefore patients with glioma harboring the IDH1 R132G mutation may be rational candidates for clinical trials investigating IDH1-inhibitors.
IDH1	R132H	Glioma	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.	The IDH1 R132H mutation is known to be oncogenic.	There is promising clinical data in patients with IDH1 R132-mutant glioma treated with the IDH1-inhibitor AG-120. Therefore patients with glioma harboring the IDH1 R132H mutation may be rational candidates for clinical trials investigating IDH1-inhibitors.
IDH1	R132Q	Glioma	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.	The IDH1 R132Q mutation is likely oncogenic.	There is promising clinical data in patients with IDH1 R132-mutant glioma treated with the IDH1-inhibitor AG-120. Therefore patients with glioma harboring the IDH1 R132Q mutation may be rational candidates for clinical trials investigating IDH1-inhibitors.
IDH1	R132I	Glioma	IDH1, a cell metabolism enzyme, is recurrently mutated in various cancers including acute myeloid leukemia and gliomas.	The IDH1 R132I mutation has not been functionally or clinically validated. However, IDH1 R132C/G/H are known to be oncogenic, and therefore IDH1 R132I is considered likely oncogenic.	There is promising clinical data in patients with IDH1 R132-mutant glioma treated with the IDH1-inhibitor AG-120. Therefore patients with glioma harboring the IDH1 R132I mutation may be rational candidates for clinical trials investigating IDH1-inhibitors.
IDH2	R172S	Non-Hodgkin Lymphoma	IDH2, which encodes the metabolic enzyme isocitrate dehydrogenase 2, is recurrently mutated in acute myeloid leukemia (AML), glioblastoma, cholangiocarcinoma, and other tumor types.	The IDH2 R172S mutation is known to be oncogenic.	While the IDH2 inhibitor enasidenib is FDA-approved for the treatment of patients with acute myeloid leukemia, its clinical utility in patients with IDH2 R172S mutant non-hodgkin lymphoma is unknown.
IDH2	R172T	Non-Hodgkin Lymphoma	IDH2, which encodes the metabolic enzyme isocitrate dehydrogenase 2, is recurrently mutated in acute myeloid leukemia (AML), glioblastoma, cholangiocarcinoma, and other tumor types.	The IDH2 R172T mutation has not been functionally or clinically validated. However, IDH2 R172K/S are known to be oncogenic, and therefore IDH2 R172T is considered likely oncogenic.	While the IDH2 inhibitor enasidenib is FDA-approved for the treatment of patients with acute myeloid leukemia, its clinical utility in patients with IDH2 R172T mutant non-hodgkin lymphoma is unknown.
IDH2	R140W	Pancreatic Cancer	IDH2, which encodes the metabolic enzyme isocitrate dehydrogenase 2, is recurrently mutated in acute myeloid leukemia (AML), glioblastoma, cholangiocarcinoma, and other tumor types.	The IDH2 R140W mutation has not been functionally or clinically validated. However, IDH2 R140Q is known to be oncogenic, and therefore IDH2 R140W is considered likely oncogenic.	While the IDH2 inhibitor enasidenib is FDA-approved for the treatment of patients with acute myeloid leukemia, its clinical utility in patients with IDH2 R140W mutant pancreatic cancer is unknown.
IDH2	R140Q	Pancreatic Cancer	IDH2, which encodes the metabolic enzyme isocitrate dehydrogenase 2, is recurrently mutated in acute myeloid leukemia (AML), glioblastoma, cholangiocarcinoma, and other tumor types.	The IDH2 R140Q mutation is known to be oncogenic.	While the IDH2 inhibitor enasidenib is FDA-approved for the treatment of patients with acute myeloid leukemia, its clinical utility in patients with IDH2 R140Q mutant pancreatic cancer is unknown.
JAK2	LRP8-JAK2 fusion	Leukemia	JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematological malignancies.	The LRP8-JAK2 fusion is likely oncogenic.	There is promising clinical data supporting the use of ruxolitinib in patients with PCM1-JAK2 fusion positive leukemia. Therefore, LRP8-JAK2 fusion positive leukemias are considered likely sensitive to the same inhibitor.
JAK2	PCM1-JAK2 Fusion	Leukemia	JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematological malignancies.	The PCM1-JAK2 fusion is likely oncogenic.	There is promising clinical data in patients with PCM1-JAK2 fusion positive leukemia treated with the FDA-approved JAK-inhibitor ruxolitinib. Therefore patients with PCM1-JAK2 fusion positive leukemia may be rational candidates for clinical trials investigating JAK-inhibitors.
JAK2	PCM1-JAK2 Fusion	Breast Cancer	JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematological malignancies.	The PCM1-JAK2 fusion is likely oncogenic.	While there is promising clinical data supporting the use of ruxolitinib in patients with PCM1-JAK2 fusion positive leukemia, its clinical utility in patients with PCM1-JAK2 fusion positive breast cancer is unknown.
JAK2	V567E	Leukemia	JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematological malignancies.	As of 03/10/2017, there was no available functional data about the JAK2 V567E mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with JAK2 V567E mutant leukemia.
JAK2	T875N	Leukemia	JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematological malignancies.	The JAK2 T875N mutation is known to be oncogenic.	While there is promising clinical data supporting the use of ruxolitinib in patients with PCM1-JAK2 fusion positive leukemia, its clinical utility in patients with JAK2 JAK2 T875N mutant leukemia is unknown.
JAK2	T875N	Breast Cancer	JAK2, an intracellular kinase, is frequently altered by mutation or chromosomal rearrangement in hematological malignancies.	The JAK2 T875N mutation is known to be oncogenic.	While there is promising clinical data supporting the use of ruxolitinib in patients with PCM1-JAK2 fusion positive leukemia, its clinical utility in patients with JAK2 JAK2 T875N mutant breast cancer is unknown.
KRAS	Q61H	Colorectal Cancer	KRAS, a GTPase, is frequently mutated in a diverse range of cancers including pancreatic, colorectal and lung cancers.	The KRAS Q61H mutation is known to be oncogenic.	This mutation represents a firm contraindication to the use of anti-EGFR agents such as cetuximab or panitumumab in patients with colorectal cancer. Not only do patients with tumors harboring this mutation not benefit from treatment with these agents, but some trials have shown a slightly worse outcome for patients with RAS-mutated tumors receiving these agents as compared to those not receiving them. There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with colon cancer harboring activating RAS mutation(s).
KRAS	G12D	Non-small cell lung cancer	KRAS, a GTPase, is frequently mutated in a diverse range of cancers including pancreatic, colorectal and lung cancers.	The KRAS G12D mutation is known to be oncogenic.	Patients with non-small cell lung cancer harboring activating KRAS mutations would be rational candidates for clinical trials investigating MEK-or ERK-inhibitors, either alone or in combination with other agents.
KRAS	G13V	Non-small cell lung cancer	KRAS, a GTPase, is frequently mutated in a diverse range of cancers including pancreatic, colorectal and lung cancers.	The KRAS G13V mutation has not been functionally or clinically validated. However, KRAS G13C/D are known to be oncogenic, and therefore KRAS G13V is considered likely oncogenic.	Patients with non-small cell lung cancer harboring activating KRAS mutations would be rational candidates for clinical trials investigating MEK-or ERK-inhibitors, either alone or in combination with other agents.
KRAS	G12V	Gastrointestinal Stromal Tumor	KRAS, a GTPase, is frequently mutated in a diverse range of cancers including pancreatic, colorectal and lung cancers.	The KRAS G12V mutation is known to be oncogenic.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KRAS G12V mutant gastrointestinal stromal tumors.
KRAS	G10dup	Nerve Sheath Tumor	KRAS, a GTPase, is frequently mutated in a diverse range of cancers including pancreatic, colorectal and lung cancers.	The KRAS G10dup alteration is known to be oncogenic.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KRAS G10dup altered nerve sheath tumors.
KRAS	Q61H	Pancreatic Cancer	KRAS, a GTPase, is frequently mutated in a diverse range of cancers including pancreatic, colorectal and lung cancers.	The KRAS Q61H mutation is known to be oncogenic.	Approximately 90% of pancreatic cancers harbor activating KRAS mutations. There are no FDA-approved or NCCN-compendium listed therapeutic options specifically for patients with pancreatic cancer harboring activating KRAS mutations.
MAP2K1	E51_Q58del	Histiocytic Disorder	MAP2K1, an intracellular kinase, is mutated at low frequencies in various cancers including melanoma, colorectal and lung cancers.	As of 07/18/2017, there was no available functional data about the MAP2K1 E51_Q58del alteration.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAP2K1 E51_Q58del altered histiocytic disorder.
MAP2K1	F53L	Histiocytic Disorder	MAP2K1, an intracellular kinase, is mutated at low frequencies in various cancers including melanoma, colorectal and lung cancers.	The MAP2K1 F53L mutation is known to be oncogenic.	There is promising clinical data in patients with histiocytic disease harboring oncogenic MAP2K1 mutations treated with the FDA-approved MEK1/2-targeted inhibitors such as cobimetinib and trametinib.
MAP2K1	F53L	Low-Grade Serous Ovarian Cancer	MAP2K1, an intracellular kinase, is mutated at low frequencies in various cancers including melanoma, colorectal and lung cancers.	The MAP2K1 F53L mutation is known to be oncogenic.	There is promising clinical data in patients with low-grade serous ovarian cancer harboring oncogenic MAP2K1 mutations treated with FDA-approved MEK1/2 targeted inhibitors such as cobimetinib and trametinib.
MAP2K1	P124L	Melanoma	MAP2K1, an intracellular kinase, is mutated at low frequencies in various cancers including melanoma, colorectal and lung cancers.	The MAP2K1 P124L mutation is likely oncogenic.	Promising laboratory and anecdotal clinical data support the use of MEK1/2-targeted inhibitors such as FDA-approved trametinib or cobimetinib in MAP2K1-mutant melanoma.
MAP2K2	P124M	Melanoma	MAP2K2 encodes a kinase involved in the pro-oncogenic MAP-kinase signaling pathway. Mutation of MAP2K2 has been shown to confer resistance to MAP-kinase pathway targeted agents in melanoma.	The MAP2K2 P124M mutation has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MAP2K2 P124M mutant melanoma.
MAP2K1	E203K	Non-small cell lung cancer	MAP2K1, an intracellular kinase, is mutated at low frequencies in various cancers including melanoma, colorectal and lung cancers.	The MAP2K1 E203K mutation is known to be oncogenic.	Patients with MAP2K1-mutant non-small cell lung cancer (NSCLC) represent a distinct subset of lung cancers (~1%) associated with smoking and occur mutually exclusively with other driver mutations in NSCLC. Promising laboratory and anecdotal clinical data support the use of MEK1/2-targeted inhibitors such as FDA-approved trametinib or cobimetinib in MAP2K1-mutant NSCLC.
MAP2K1	K57N	Gastrointestinal Stromal Tumor	MAP2K1, an intracellular kinase, is mutated at low frequencies in various cancers including melanoma, colorectal and lung cancers.	The MAP2K1 K57N mutation is known to be oncogenic.	While there is promising clinical data supporting the use of FDA-approved MEK1/2 targeted inhibitors such as cobimetinib and trametinib in patients with histiocytic disease and ovarian cancer harboring known oncogenic MAP2K1 mutations, their clinical utility in patients with MAP2K1 K57N mutant gastrointestinal stromal tumors is unknown.
MET	981_1028splice	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET 981_1028splice alteration is known to be oncogenic.	Crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations.
MET	963_D1010splice	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET 963_D1010splice alteration is known to be oncogenic.	Crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations.
MET	X963_splice	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET X963_splice alteration is known to be oncogenic.	Crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations.
MET	X1006_splice	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET X1006_splice alteration is known to be oncogenic.	Crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations.
MET	X1007_splice	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET X1007_splice alteration is known to be oncogenic.	Crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations.
MET	X1008_splice	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET X1008_splice alteration is known to be oncogenic.	Crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations.
MET	X1009_splice	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET X1009_splice alteration is known to be oncogenic.	Crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations.
MET	X1010_splice	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET X1010_splice alteration is known to be oncogenic.	Crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations.
MET	981_1028splice	Endometrial Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET 981_1028splice alteration is known to be oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations, its clinical utility in patients with MET exon 14 altered endometrial cancer is unknown.
MET	963_D1010splice	Endometrial Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET 963_D1010splice alteration is known to be oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations, its clinical utility in patients with MET exon 14 altered endometrial cancer is unknown.
MET	X963_splice	Endometrial Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET X963_splice alteration is known to be oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations, its clinical utility in patients with MET exon 14 altered endometrial cancer is unknown.
MET	X1006_splice	Endometrial Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET X1006_splice alteration is known to be oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations, its clinical utility in patients with MET exon 14 altered endometrial cancer is unknown.
MET	X1007_splice	Gastrointestinal Stromal Tumor	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET X1007_splice alteration is known to be oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations, its clinical utility in patients with MET exon 14 altered gastrointestinal stromal tumors is unknown.
MET	X1008_splice	Gastrointestinal Stromal Tumor	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET X1008_splice alteration is known to be oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations, its clinical utility in patients with MET exon 14 altered gastrointestinal stromal tumors is unknown.
MET	X1009_splice	Gastrointestinal Stromal Tumor	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET X1009_splice alteration is known to be oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations, its clinical utility in patients with MET exon 14 altered gastrointestinal stromal tumors is unknown.
MET	X1010_splice	Gastrointestinal Stromal Tumor	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET X1010_splice alteration is known to be oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations, its clinical utility in patients with MET exon 14 altered gastrointestinal stromal tumors is unknown.
MET	M1250T	Renal Cell Carcinoma	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET M1250T mutation is known to be oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations and MET amplification, its clinical utility in patients with MET M1250T mutant renal cell carcinoma is unknown.
MET	Y1230S	Renal Cell Carcinoma	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET Y1230S mutation has not been functionally or clinically validated. However, MET Y1230H is known to be oncogenic, and therefore MET Y1230S is considered likely oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations and MET amplification, its clinical utility in patients with MET Y1230S mutant renal cell carcinoma is unknown.
MET	Amplification	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	MET amplification is known to be oncogenic.	Crizotinib is NCCN-compendium listed for the treatment of patients with high-level MET-amplified lung cancer.
MET	Amplification	Gastrointestinal Stromal Tumor	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	MET amplification is known to be oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with high-level MET-amplified lung cancer, its clinical utility in patients with MET-amplified gastrointestinal stromal tumors is unknown.
MET	D101H	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET D101H mutation has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET D101H mutant non-small cell lung cancer.
MET	D1010H	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET D1010H mutation is likely oncogenic.	Crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations such as MET D1010H.
MET	D1010Y	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET D1010Y mutation is likely oncogenic.	Crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations such as MET D1010Y.
MET	D1010H	Gastrointestinal Stromal Tumor	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET D1010H mutation is likely oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations such as D1010H, its clinical utility in patients with MET D1010H mutant gastrointestinal stromal tumors is unknown.
MET	D101H	Gastrointestinal Stromal Tumor	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET D101H mutation has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET D101H mutant gastrointestinal stromal tumors.
MET	D1010Y	Gastrointestinal Stromal Tumor	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET D1010Y mutation is likely oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations such as D1010Y, its clinical utility in patients with MET D1010Y mutant gastrointestinal stromal tumors is unknown.
MET	D1010N	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET D1010N mutation is likely oncogenic.	Crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations such as MET D1010N.
MET	D1010N	Gastrointestinal Stromal Tumor	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET D1010N mutation is likely oncogenic.	While crizotinib is NCCN-compendium listed for the treatment of patients with lung cancer harboring MET exon 14 alterations such as D1010N, its clinical utility in patients with MET D1010N mutant gastrointestinal stromal tumors is unknown.
MET	D101N	Gastrointestinal Stromal Tumor	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	The MET D101N mutation has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET D101N mutant gastrointestinal stromal tumors.
MET	MET-SLC1A2 fusion	Non-Small Cell Lung Cancer	MET, a receptor tyrosine kinase, is recurrently altered by mutation, amplification and/or overexpression in various cancers.	As of 08/01/2017, there was no available functional data about the MET-SLC1A2 fusion.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MET-SLC1A2 fusion positive non-small cell lung cancer.
MTOR	I2500M	Bladder Cancer	MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in a diverse range of cancers.	The MTOR I2500M mutation is likely oncogenic.	While there is promising clinical data supporting the use of everolimus in patients with MTOR E2014K mutant bladder cancer, its clinical utility in patients with MTOR I2500M mutant bladder cancer is unknown.
MTOR	I2500M	Salivary Gland Cancer	MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in a diverse range of cancers.	The MTOR I2500M mutation is likely oncogenic.	While there is promising clinical data supporting the use of everolimus in patients with MTOR E2014K mutant bladder cancer, its clinical utility in patients with MTOR I2500M mutant salivary gland cancer is unknown.
MTOR	E2014K	Bladder Cancer	MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in a diverse range of cancers.	The MTOR E2014K mutation is likely oncogenic.	There is promising clinical data in patients with MTOR E2014K mutant bladder cancer treated with the FDA-approved MTOR-inhibitor everolimus. Therefore, patients with bladder cancer harboring the MTOR E2014K mutation may be rational candidates for clinical trials investigating MTOR-inhibitors.
MTOR	E2014K	Gastrointestinal Stromal Tumor	MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in a diverse range of cancers.	The MTOR E2014K mutation is likely oncogenic.	While there is promising clinical data supporting the use of everolimus in patients with MTOR E2014K mutant bladder cancer, its clinical utility in patients with MTOR E2014K mutant gastrointestinal stromal tumors is unknown.
MTOR	E201N	Bladder Cancer	MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in a diverse range of cancers.	The MTOR E201N mutation has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR E201N mutant bladder cancer.
MTOR	E201N	Gastrointestinal Stromal Tumor	MTOR, an intracellular kinase that regulates cell growth and metabolism, is infrequently mutated in a diverse range of cancers.	The MTOR E201N mutation has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with MTOR E201N mutant gastrointestinal stromal tumors.
NRAS	G12D	Colorectal Cancer	NRAS, a GTPase, is mutated in a diverse range of cancers, most frequently in melanoma and thyroid cancer.	The NRAS G12D mutation is known to be oncogenic.	As with all RAS mutations, this mutation represents a firm contraindication to the use of anti-EGFR agents such as cetuximab or panitumumab in patients with colorectal cancer. Not only do patients with tumors harboring this mutation not benefit from treatment with these agents, but some trials have shown a slightly worse outcome for patients with RAS-mutated tumors receiving these agents as compared to those not receiving them.
NRAS	G12R	Colorectal Cancer	NRAS, a GTPase, is mutated in a diverse range of cancers, most frequently in melanoma and thyroid cancer.	The NRAS G12R mutation is known to be oncogenic.	As with all RAS mutations, this mutation represents a firm contraindication to the use of anti-EGFR agents such as cetuximab or panitumumab in patients with colorectal cancer. Not only do patients with tumors harboring this mutation not benefit from treatment with these agents, but some trials have shown a slightly worse outcome for patients with RAS-mutated tumors receiving these agents as compared to those not receiving them.
NRAS	Q61R	Melanoma	NRAS, a GTPase, is mutated in a diverse range of cancers, most frequently in melanoma and thyroid cancer.	The NRAS Q61R mutation is known to be oncogenic.	There is promising clinical data in patients with melanoma harboring oncogenic NRAS mutations treated with the MEK-inhibitor binimetinib, either as monotherapy or in combination with the CDK4/6-inhibitor, ribociclib. Therefore, patients with melanoma harboring the NRAS Q61R mutation may be rational candidates for clinical trials investigating MEK-inhibitors.
NRAS	Q61R	Gastrointestinal Stromal Tumor	NRAS, a GTPase, is mutated in a diverse range of cancers, most frequently in melanoma and thyroid cancer.	The NRAS Q61R mutation is known to be oncogenic.	While there is promising clinical data supporting the use of MEK-inhibitors such as binimetinib, either as monotherapy or in combination with the CDK4/6 inhibitor ribociclib in patients with melanoma harboring oncogenic NRAS mutations, their clinical utility in patients with NRAS Q61R mutant gastrointestinal stromal tumors is unknown.
NRAS	Q61R	Thyroid Cancer	NRAS, a GTPase, is mutated in a diverse range of cancers, most frequently in melanoma and thyroid cancer.	The NRAS Q61R mutation is known to be oncogenic.	There is promising clinical data in patients with thyroid cancer harboring oncogenic NRAS mutations treated with the FDA-approved MEK-inhibitor selumetinib, both in combination with or as upfront therapy prior to radioiodine uptake therapy.
NRAS	CSDE1-NRAS fusion	Glioma	NRAS, a GTPase, is mutated in a diverse range of cancers, most frequently in melanoma and thyroid cancer.	As of 09/06/2017, there was no available functional data about the CSDE1-NRAS fusion.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with CSDE1-NRAS fusion positive glioma.
NTRK1	R342W	Endometrial Cancer	NTRK1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in various cancers including lung and colorectal cancers.	The NTRK1 R342W mutation is likely oncogenic.	While there is promising clinical data supporting the use of TRK-inhibitors such as entrectinib and LOXO-101 in patients with NTRK1-fusion positive cancer, their clinical utility in patients with NTRK1 R342W mutant endometrial cancer is unknown.
NTRK1	NTRK1-LMNA fusion	Colorectal Cancer	NTRK1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in various cancers including lung and colorectal cancers.	The NTRK1-LMNA fusion is known to be oncogenic.	There is promising clinical data supporting the use of the TRK-inhibitors larotrectinib and entrectinib as single agents in patients with NTRK1-fusion positive cancers. Therefore patients with NTRK1-LMNA fusion positive colorectal cancer may be rational candidates for clinical trials investigating TRK-inhibitors.
NTRK1	NTRK1-ZBTB7B fusion	Salivary Gland Cancer	NTRK1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in various cancers including lung and colorectal cancers.	The NTRK1-ZBTB7B fusion is likely oncogenic.	There is promising clinical data supporting the use of the TRK-inhibitors larotrectinib and entrectinib as single agents in patients with NTRK1-fusion positive cancers. Therefore patients with NTRK1-ZBTB7B fusion positive salivary gland cancer may be rational candidates for clinical trials investigating TRK-inhibitors.
NTRK2	Oncogenic Mutations	All Tumors	NTRK2, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers.	The NTRK2 oncogenic mutations has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	While there is promising clinical data supporting the use of TRK-inhibitors such as entrectinib and larotrectinib in patients with NTRK2-fusion positive salivary gland cancer, their clinical utility in patients with NTRK2 oncogenic mutations all tumors is unknown.
NTRK2	NTRK2-APOL3 fusion	Prostate Cancer	NTRK2, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers.	The NTRK2-APOL3 fusion is likely oncogenic.	There is promising clinical data supporting the use of the TRK-inhibitors larotrectinib and entrectinib as single agents in patients with NTRK2-fusion positive cancers. Therefore patients with NTRK2-APOL3 fusion positive prostate cancer may be rational candidates for clinical trials investigating TRK-inhibitors.
NTRK2	NTRK2-APOL3 fusion	Salivary Gland Cancer	NTRK2, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers.	The NTRK2-APOL3 fusion is likely oncogenic.	There is promising clinical data supporting the use of the TRK-inhibitors larotrectinib and entrectinib as single agents in patients with NTRK2-fusion positive cancers. Therefore patients with NTRK2-APOL3 fusion positive salivary gland cancer may be rational candidates for clinical trials investigating TRK-inhibitors.
NTRK3	Oncogenic Mutations	All Tumors	NTRK3, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers including melanoma and lung cancers.	The NTRK3 oncogenic mutations has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	While there is promising clinical data supporting the use of TRK-inhibitors entrectinib and larotrectinib in patients with NTRK3-fusion positive salivary gland cancer, their clinical utility in patients with NTRK3 oncogenic mutations all tumors is unknown.
NTRK3	G623R	Colorectal cancer	NTRK3, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers including melanoma and lung cancers.	There is conflicting and/or weak data describing the oncogenic function of the NTRK3 G623R mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with NTRK3 G623R mutant colorectal cancer.
NTRK3	ETV6-NTRK3 fusion	Colorectal Cancer	NTRK3, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers including melanoma and lung cancers.	The ETV6-NTRK3 fusion is known to be oncogenic.	There is promising clinical data supporting the use of the TRK-inhibitors larotrectinib and entrectinib as single agents in patients with NTRK3-fusion positive cancers. Therefore patients with ETV6-NTRK3 fusion positive colorectal cancer may be rational candidates for clinical trials investigating TRK-inhibitors.
NTRK3	ETV6-NTRK3 fusion	Salivary Gland Cancer	NTRK3, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers including melanoma and lung cancers.	The ETV6-NTRK3 fusion is known to be oncogenic.	There is promising clinical data in patients with NTRK3-fusion positive salivary gland cancer treated with the TRK-inhibitors entrectinib and larotrectinib. Therefore patients with ETV6-NTRK3 fusion positive salivary gland cancer may be rational candidates for clinical trials investigating TRK-inhibitors.
PDGFRA	FIP1L1-PDGFRA fusion	Leukemia	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The FIP1L1-PDGFRA fusion is known to be oncogenic.	Imatinib is FDA-approved for the treatment of patients with FIP1L1-PDGFRA fusion positive hypereosinophilic syndrome and chronic eosinophilic leukemia.
PDGFRA	FIP1L1-PDGFRA fusion	Other Tumor Types	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The FIP1L1-PDGFRA fusion is known to be oncogenic.	While imatinib is FDA-approved for the treatment of patients with FIP1L1-PDGFRA fusion positive hypereosinophilic syndrome and chronic eosinophilic leukemia, its clinical utility in patients with FIP1L1-PDGFRA fusion positive other tumor types is unknown.
PDGFRA	EXOC1-PDGFRA fusion	Myelodysplasia	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The EXOC1-PDGFRA fusion is likely oncogenic.	Imatinib is FDA-approved for the treatment of patients with PDGFRA-fusion positive myelodysplastic and myeloproliferative diseases.
PDGFRA	EXOC1-PDGFRA fusion	Myeloproliferative Neoplasm	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The EXOC1-PDGFRA fusion is likely oncogenic.	Imatinib is FDA-approved for the treatment of patients with PDGFRA-fusion positive myelodysplastic and myeloproliferative diseases.
PDGFRA	EXOC1-PDGFRA fusion	Soft Tissue Sarcoma	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The EXOC1-PDGFRA fusion is likely oncogenic.	While imatinib is FDA-approved for the treatment of patients with PDGFRA fusion positive myelodysplastic and myeloproliferative diseases, its clinical utility in patients with PDGFRA-fusion positive soft tissue sarcoma is unknown.
PDGFRA	V561D	Gastrointestinal Stromal Tumor	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The PDGFRA V561D mutation is known to be oncogenic.	Imatinib is NCCN-compendium listed for the treatment of patients with gastrointestinal stromal tumors (GISTs) harboring activating PDGFRA alterations such as V561D.
PDGFRA	V561L	Gastrointestinal Stromal Tumor	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The PDGFRA V561L mutation has not been functionally or clinically validated. However, PDGFRA V561A/D are known to be oncogenic, and therefore PDGFRA V561L is considered likely oncogenic.	Imatinib is NCCN-compendium listed for the treatment of patients with gastrointestinal stromal tumors (GISTs) harboring activating PDGFRA alterations such as V561L.
PDGFRA	P577L	Endometrial Cancer	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The PDGFRA P577L mutation has not been functionally or clinically validated. However, PDGFRA P577S is likely oncogenic, and therefore PDGFRA P577L is considered likely oncogenic.	While imatinib is NCCN-compendium listed for the treatment of patients with gastrointestinal stromal tumors harboring activating PDGFRA alterations such as P577L, its clinical utility in patients with PDGFRA P577L mutant endometrial cancer is unknown.
PDGFRA	P659Y	Glioma	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The PDGFRA P659Y mutation has not been functionally or clinically validated. However, PDGFRA N659K/R/S are likely oncogenic, and therefore PDGFRA P659Y is considered likely oncogenic.	While imatinib is NCCN-compendium listed for the treatment of patients with gastrointestinal stromal tumors harboring activating PDGFRA alterations such as P659Y, its clinical utility in patients with PDGFRA P659Y mutant glioma is unknown.
PDGFRA	D824V	Gastrointestinal Stromal Tumor	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The PDGFRA D824V mutation has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PDGFRA D824V mutant gastrointestinal stromal tumors.
PDGFRA	D842Y	Gastrointestinal Stromal Tumor	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The PDGFRA D842Y mutation is likely oncogenic.	Imatinib is NCCN-compendium listed for the treatment of patients with gastrointestinal stromal tumors (GISTs) harboring activating PDGFRA alterations such as D842Y.
PDGFRA	D842I	Gastrointestinal Stromal Tumor	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The PDGFRA D842I mutation is likely oncogenic.	Imatinib is NCCN-compendium listed for the treatment of patients with gastrointestinal stromal tumors (GISTs) harboring activating PDGFRA alterations such as D842I.
PDGFRA	D842I	Embryonal Tumor	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The PDGFRA D842I mutation is likely oncogenic.	Patients with PDGFRA D842V mutant gastrointestinal stromal tumors (GISTs) do not respond to imatinib. While, dasatinib is NCCN-compendium listed for the treatment of patients with PDGFRA D842V mutant GIST, its clinical utility in patients with D842V mutant embryonal tumors is unknown.
PDGFRA	?	Gastrointestinal Stromal Tumor	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The PDGFRA ? mutation has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PDGFRA ? mutant gastrointestinal stromal tumors.
PDGFRA	K830R	Gastrointestinal Stromal Tumor	PDGFRA, a receptor tyrosine kinase, is altered by mutation, chromosomal rearrangement or amplifications in a diverse range of cancers.	The PDGFRA K830R mutation is likely neutral.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PDGFRA K830R mutant gastrointestinal stromal tumors.
PDGFRB	R561P	Non-Small Cell Lung Cancer	PDGFRB, a receptor tyrosine kinase, is infrequently mutated in solid tumors.	The PDGFRB R561P mutation has not been functionally or clinically validated.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PDGFRB R561P mutant non-small cell lung cancer.
PDGFRB	PDGFRB-CSF1R fusion	Dermatofibrosarcoma Protuberans	PDGFRB, a receptor tyrosine kinase, is infrequently mutated in solid tumors.	The PDGFRB-CSF1R fusion is likely oncogenic.	Imatinib is FDA-approved for the treatment of patients with dermatofibrosarcoma protuberans, which frequently harbor PDGFRB fusions.
PDGFRB	PDGFRB-CSF1R fusion	Myelodisplasia	PDGFRB, a receptor tyrosine kinase, is infrequently mutated in solid tumors.	The PDGFRB-CSF1R fusion is likely oncogenic.	While imatinib is FDA-approved for the treatment of patients with PDGFRB-fusion positive myelodysplastic and myeloproliferative diseases, its clinical utility in patients with PDGFRB-fusion positive myelodisplasia is unknown.
PDGFRB	PDGFRB-CSF1R fusion	Myeloproliferative Neoplasm	PDGFRB, a receptor tyrosine kinase, is infrequently mutated in solid tumors.	The PDGFRB-CSF1R fusion is likely oncogenic.	Imatinib is FDA-approved for the treatment of patients with PDGFRB-fusion positive myeloproliferative disease.
PDGFRB	PDGFRB-CSF1R fusion	Gastrointestinal Stromal Tumor	PDGFRB, a receptor tyrosine kinase, is infrequently mutated in solid tumors.	The PDGFRB-CSF1R fusion is likely oncogenic.	While imatinib is FDA-approved for the treatment of patients with PDGFRB-fusion positive myelodysplastic and myeloproliferative diseases, its clinical utility in patients with PDGFRB-fusion positive gastrointestinal stromal tumors is unknown.
PIK3CA	Q546P	Breast Cancer	PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers, including breast, endometrial and cervical cancers.	The PIK3CA Q546P mutation is known to be oncogenic.	There is promising clinical data in patients with ER+/HER2- breast cancer harboring oncogenic PIK3CA mutations treated with multiple different PI3-kinase targeted inhibitors, either alone or in combination with ER-antagonists such as fulvestrant.
PIK3CA	Q546P	Colorectal Cancer	PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers, including breast, endometrial and cervical cancers.	The PIK3CA Q546P mutation is known to be oncogenic.	PIK3CA mutations commonly occur in colorectal cancer and co-occur with RAS mutation in about two-thirds of cases. There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CA Q546P mutant colorectal cancer.
PIK3CA	H1047L	Gastrointestinal Stromal Tumor	PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers, including breast, endometrial and cervical cancers.	The PIK3CA H1047L mutation is known to be oncogenic.	While there is promising clinical data supporting the use of PI3K-targeted inhibitors, either alone or in combination with ER-antagonists such as fulvestrant, in patients with ER+/HER2- breast cancer harboring oncogenic PIK3CA mutations, their clinical utility in patients with PIK3CA H1047L mutant gastrointestinal stromal tumors is unknown.
PIK3CA	G106_R108del	Colorectal Cancer	PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers, including breast, endometrial and cervical cancers.	The PIK3CA G106_R108del alteration is likely oncogenic.	PIK3CA mutations commonly occur in colorectal cancer and co-occur with RAS mutation in about two-thirds of cases. There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CA G106_R108del altered colorectal cancer.
PIK3CA	H450_L455del	Breast Cancer	PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers, including breast, endometrial and cervical cancers.	The PIK3CA H450_L455del alteration is known to be oncogenic.	There is promising clinical data in patients with ER+/HER2- breast cancer harboring oncogenic PIK3CA mutations treated with multiple different PI3-kinase targeted inhibitors, either alone or in combination with ER-antagonists such as fulvestrant.
PIK3CA	K111del	Endometrial Cancer	PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers, including breast, endometrial and cervical cancers.	As of 03/02/2017, there was no available functional data about the PIK3CA K111del alteration.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with PIK3CA K111del altered endometrial cancer.
PTCH1	X1034_splice	Endometrial Cancer	PTCH1, a tumor suppressor and inhibitor of the hedgehog pathway, is recurrently mutated in basal cell carcinoma.	The PTCH1 X1034_splice alteration is likely oncogenic.	While there is promising clinical data supporting the use of hedgehog pathway inhibitors such as sonidegib and vismodegib in patients with basal cell carcinoma harboring truncating PTCH1 mutations, their clinical utility in patients with PTCH1 X1034_splice altered endometrial cancer is unknown.
PTCH1	G492*	Embryonal Tumor	PTCH1, a tumor suppressor and inhibitor of the hedgehog pathway, is recurrently mutated in basal cell carcinoma.	The PTCH1 G492* mutation is likely oncogenic.	There is promising clinical data in patients with embryonal tumors harboring truncating PTCH1 mutations treated with the hedgehog pathway inhibitor sonidegib. Therefore patients with embryonal tumors harboring the PTCH1 G492* mutation may be rational candidates for clinical trials investigating hedgehog pathway inhibitors.
PTCH1	S1203Afs*52	Esophagogastric Cancer	PTCH1, a tumor suppressor and inhibitor of the hedgehog pathway, is recurrently mutated in basal cell carcinoma.	The PTCH1 S1203Afs*52 mutation is likely oncogenic.	While there is promising clinical data supporting the use of hedgehog pathway inhibitors such as sonidegib and vismodegib in patients with basal cell carcinoma harboring truncating PTCH1 mutations, their clinical utility in patients with PTCH1 S1203Afs*52 mutant esophagogastric cancer is unknown.
RET	R886W	Prostate Cancer	RET, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in various cancers including thyroid and lung cancers.	The RET R886W mutation is known to be oncogenic.	While cabozantinib is NCCN-compendium listed for the treatment of patients with RET-fusion positive lung cancer, its clinical utility in patients with RET R886W mutant prostate cancer is unknown.
RET	EML4-RET fusion	Non-Small Cell Lung Cancer	RET, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in various cancers including thyroid and lung cancers.	The EML4-RET fusion is likely oncogenic.	Cabozantinib is NCCN-compendium listed for the treatment of patients with RET-fusion positive non-small cell lung cancer.
RET	RET-NCOA4 fusion	Thyroid Cancer	RET, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in various cancers including thyroid and lung cancers.	The RET-NCOA4 fusion is likely oncogenic.	While cabozantinib is NCCN-compendium listed for the treatment of patients with RET-fusion positive non-small cell lung cancer, its clinical utility in patients with RET-fusion positive thyroid cancer is unknown.
ROS1	S1986F	Ovarian Cancer	ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	The ROS1 S1986F mutation is likely oncogenic.	While crizotinib is FDA-approved for the treatment of patients with ROS1-fusion positive non-small cell lung cancer, its clinical utility in patients with ROS1 S1986F mutant ovarian cancer is unknown.
ROS1	D2033N	Non-Small Cell Lung Cancer	ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	The ROS1 D2033N mutation is likely oncogenic.	While crizotinib is FDA-approved for the treatment of patients with ROS1-fusion positive non-small cell lung cancer, its clinical utility in patients with ROS1 D2033N mutant non-small cell lung cancer is unknown.
ROS1	D2033N	Gastrointestinal Stromal Tumor	ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	The ROS1 D2033N mutation is likely oncogenic.	While crizotinib is FDA-approved for the treatment of patients with ROS1-fusion positive non-small cell lung cancer, its clinical utility in patients with ROS1 D2033N mutant gastrointestinal stromal tumors is unknown.
ROS1	EZR-ROS1 fusion	Non-Small Cell Lung Cancer	ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	The EZR-ROS1 fusion is known to be oncogenic.	Crizotinib is FDA-approved for the treatment of patients with ROS1-fusion positive non-small cell lung cancer.
ROS1	ROS1-SLC4A4 fusion	Pancreatic Cancer	ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.	The ROS1-SLC4A4 fusion is likely oncogenic.	While crizotinib is FDA-approved for the treatment of patients with ROS1-fusion positive non-small cell lung cancer, its clinical utility in patients with ROS1-fusion positive pancreatic cancer is unknown.
TSC1	E232*	CNS Cancer	TSC1, a tumor suppressor in the mTOR signaling pathway, is inactivated by mutation or deletion in various cancers, most frequently in bladder cancer.	The TSC1 E232* mutation is likely oncogenic.	Everolimus is considered standard care for the treatment of patients with subependymal giant cell astrocytomas harboring inactivating TSC1 or TSC2 alterations such as TSC1 E232*.
TSC1	X797_splice	Endometrial Cancer	TSC1, a tumor suppressor in the mTOR signaling pathway, is inactivated by mutation or deletion in various cancers, most frequently in bladder cancer.	The TSC1 X797_splice alteration is likely oncogenic.	While everolimus is considered standard care for the treatment of patients with subependymal giant cell astrocytomas harboring inactivating TSC1 or TSC2 alterations, its clinical utility in patients with TSC1 X797_splice altered endometrial cancer is unknown.
TSC2	T417I	Prostate Cancer	TSC2, a tumor suppressor in the mTOR signaling pathway, is inactivated by mutation or deletion in a diverse range of cancers.	The TSC2 T417I mutation has not specifically been reviewed by the OncoKB team, and its oncogenic function is considered unknown.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with TSC2 T417I mutant prostate cancer.
TSC2	W1060*	CNS Cancer	TSC2, a tumor suppressor in the mTOR signaling pathway, is inactivated by mutation or deletion in a diverse range of cancers.	The TSC2 W1060* mutation is likely oncogenic.	Everolimus is considered standard care for the treatment of patients with subependymal giant cell astrocytomas harboring inactivating TSC1 or TSC2 alterations such as TSC2 W1060*.
TSC2	X75_splice	Colorectal Cancer	TSC2, a tumor suppressor in the mTOR signaling pathway, is inactivated by mutation or deletion in a diverse range of cancers.	The TSC2 X75_splice alteration is likely oncogenic.	While everolimus is considered standard care for the treatment of patients with subependymal giant cell astrocytomas harboring inactivating TSC1 or TSC2 alterations, its clinical utility in patients with TSC2 X75_splice altered colorectal cancer is unknown.
KIT	V560D	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT V560D mutation is known to be oncogenic.	Regorafenib is FDA-approved for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib and sunitinib. Patients with GISTs harboring the KIT V560D mutation may experience clinical benefit following treatment with regorafenib.
KIT	H697Y	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT H697Y mutation is known to be oncogenic.	Sunitinib is FDA-approved for the treatment of patients with gastrointestinal stromal tumors (GISTs) after disease progression on or patient intolerance to imatinib. Patients with GISTs harboring the KIT H697Y mutation may experience clinical benefit following treatment with sunitinib.
KIT	N822K	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT N822K mutation is known to be oncogenic.	Regorafenib is FDA-approved for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib and sunitinib. Patients with GISTs harboring the KIT N822K mutation may experience clinical benefit following treatment with regorafenib.
KIT	P577_D579del	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT P577_D579del alteration is likely oncogenic.	Sorafenib is a KIT-inhibitor that is NCCN-compendium listed for the treatment of patients with KIT-mutant gastrointestinal stromal tumors who have previously been treated with and progressed on the FDA-approved KIT inhibitors imatinib, sunitinib and regorafenib. Patients with GISTs harboring the KIT P577_D579del alteration may experience clinical benefit following treatment with sorafenib.
KIT	D816V	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT D816V mutation is known to be oncogenic.	The KIT D816V mutation lies in exon 17 of KIT and typically occurs in patients with gastrointestinal stromal tumors in the setting of imatinib or sunitinib resistance.
KIT	D816F	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT D816F mutation is known to be oncogenic.	The KIT D816F mutation lies in exon 17 of KIT and typically occurs in patients with gastrointestinal stromal tumors in the setting of imatinib or sunitinib resistance.
KIT	K642E	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT K642E mutation is likely oncogenic.	Sorafenib is a KIT-inhibitor that is NCCN-compendium listed for the treatment of patients with KIT-mutant gastrointestinal stromal tumors who have previously been treated with and progressed on the FDA-approved KIT inhibitors imatinib, sunitinib and regorafenib. Patients with GISTs harboring the KIT K642E mutation may experience clinical benefit following treatment with sorafenib.
KIT	V559D	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT V559D mutation is known to be oncogenic.	Dasatinib is a KIT-inhibitor that is NCCN-compendium listed for the treatment of patients with KIT-mutant gastrointestinal stromal tumors who have previously been treated with and progressed on the FDA-approved KIT inhibitors imatinib, sunitinib and regorafenib. Patients with GISTs harboring the KIT V559D mutation may experience clinical benefit following treatment with dasatinib.
KIT	W557R	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT W557R mutation is likely oncogenic.	Imatinib is FDA-approved for the treatment of patients with KIT-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs). Patients with GISTs harboring the KIT W557R mutation may experience clinical benefit following treatment with imatinib.
KIT	D496N	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT D496N mutation is known to be oncogenic.	The KIT D496N mutation lies in exon 9 of KIT. The multikinase KIT and PDGFRA inhibitors imatinib, sunitinib and regorafenib are FDA-approved for the treatment of patients with gastrointestinal stromal tumors (GISTs) harboring KIT exon 9 alterations. The NCCN states that approximately 50% of patients with advanced GIST harboring KIT exon 9 mutations experience clinical benefit when treated with standard-dose 400 mg imatinib and that the use of high-dose 800 mg imatinib or standard-dose sunitinib improves the likelihood of response for these patients.
KIT	V559A	Melanoma	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT V559A mutation is likely oncogenic.	Imatinib is NCCN-compendium listed for the treatment of patients with metastatic or unresectable melanoma with activating mutations of KIT.
KIT	V560D	Thymic Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT V560D mutation is known to be oncogenic.	Sunitinib is NCCN-compendium listed as a targeted therapy option for the treatment of patients with KIT-positive thymic cancer.
KIT	K642E	Thymic Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT K642E mutation is likely oncogenic.	Sorafenib is NCCN-compendium listed as a targeted therapy option for the treatment of patients with KIT-positive thymic cancer.
KIT	D816V	Thymic Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT D816V mutation is known to be oncogenic.	While the KIT D816V mutation lies in exon 17 of KIT and typically occurs in patients with gastrointestinal stromal tumors in the setting of imatinib or sunitinib resistance, the clinical significance of this mutation in patients with KIT D816V mutant thymic tumors is unknown.
KIT	V560D	Breast Cancer	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT V560D mutation is known to be oncogenic.	While patients with gastrointestinal stromal tumors harboring the KIT V560D mutation may respond to regorafenib, its clinical utility in patients with KIT V560D mutant breast cancer is unknown.
KIT	H697Y	Breast Cancer	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT H697Y mutation is known to be oncogenic.	While patients with gastrointestinal stromal tumors harboring the KIT H697Y mutation may respond to sunitinib, its clinical utility in patients with KIT H697Y mutant breast cancer is unknown.
KIT	N822K	Breast Cancer	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT N822K mutation is known to be oncogenic.	While patients with gastrointestinal stromal tumors harboring the KIT N822K mutation may respond to regorafenib, its clinical utility in patients with KIT N822K mutant breast cancer is unknown.
KIT	P577_D579del	Breast Cancer	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT P577_D579del alteration is likely oncogenic.	While patients with gastrointestinal stromal tumors harboring the KIT P577_D579del alteration may respond to sorafenib, its clinical utility in patients with KIT P577_D579del altered breast cancer is unknown.
KIT	D816V	Breast Cancer	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT D816V mutation is known to be oncogenic.	While the KIT D816V mutation lies in exon 17 of KIT and typically occurs in patients with gastrointestinal stromal tumors in the setting of imatinib or sunitinib resistance, the clinical significance of this mutation in patients with KIT D816V mutant breast cancer is unknown.
KIT	D816F	Breast Cancer	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT D816F mutation is known to be oncogenic.	While the KIT D816F mutation lies in exon 17 of KIT and typically occurs in patients with gastrointestinal stromal tumors in the setting of imatinib or sunitinib resistance, the clinical significance of this mutation in patients with KIT D816F mutant breast cancer is unknown.
KIT	V559A	Breast Cancer	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT V559A mutation is likely oncogenic.	While imatinib is NCCN-compendium listed for the treatment of patients with metastatic or unresectable melanoma with activating KIT mutations, its clinical utility in patients with KIT V559A mutant breast cancer is unknown.
KIT	R634W	Breast Cancer	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT R634W mutation is known to be oncogenic.	While imatinib, sunitinib and regorafenib are FDA-approved for the treatment of patients with KIT-positive gastrointestinal stromal tumors (GIST), their clinical utility in patients with KIT R634W mutant breast cancer is unknown.
KIT	E839K	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT E839K mutation is likely neutral.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KIT E839K mutant gastrointestinal stromal tumors.
KIT	R888W	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	As of 08/02/2016, there was no available functional data about the KIT R888W mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with KIT R888W mutant gastrointestinal stromal tumors.
KIT	K642Q	Gastrointestinal Stromal Tumor	KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.	The KIT K642Q mutation has not been functionally or clinically validated. However, KIT K642E is likely oncogenic, and therefore KIT K642Q is considered likely oncogenic.	Sorafenib is a KIT-inhibitor that is NCCN-compendium listed for the treatment of patients with KIT-mutant gastrointestinal stromal tumors who have previously been treated with and progressed on the FDA-approved KIT inhibitors imatinib, sunitinib and regorafenib. Patients with GISTs harboring the KIT K642Q mutation may experience clinical benefit following treatment with sorafenib.

#Inconclusive summary test
FOXL2	Amplification	Colorectal Cancer	FOXL2, a transcription factor involved in ovarian development, is recurrently mutated in adult granulosa cell tumors.	There is conflicting and/or weak data describing the oncogenic function of the FOXL2 amplification.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with FOXL2-amplified colorectal cancer.
AR	Q58L	Colorectal Cancer	AR encodes the androgen receptor, a steroid-hormone activated transcription factor. AR is frequently altered in advanced stages of prostate cancer.	There is conflicting and/or weak data describing the oncogenic function of the AR Q58L mutation.	There are no FDA-approved or NCCN-compendium listed treatments specifically for patients with AR Q58L mutant colorectal cancer.
